SUMMARY

Purpose

The management of advanced prostate cancer is rapidly evolving. To assist in clinical decision-making, evidence-based guideline statements were developed to provide a rational basis for evidence-based treatment. This guideline covers advanced prostate cancer, including disease stages that range from prostate-specific antigen (PSA) recurrence after exhaustion of local treatment options to widespread metastatic disease.

Methodology

The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. A research librarian conducted searches in Ovid MEDLINE (1998 to January Week 5 2019), Cochrane Central Register of Controlled Trials (through December 2018), and Cochrane Database of Systematic Reviews (2005 through February 6, 2019). An updated search was conducted prior to publication through January 20, 2020. In 2023, the Advanced Prostate Cancer guideline was updated through the AUA amendment process in which newly published literature is reviewed and integrated into previously published guidelines. The methodology team searched Ovid MEDLINE(R) ALL and the Cochrane Libraries for studies published between 2018 and March 16, 2022. Following initial report review, the Panel suggested additional abstracts that were assessed for inclusion as well.

GUIDELINE STATEMENTS

EARLY EVALUATION AND COUNSELING

1. In patients with suspicion of advanced prostate cancer and no prior histologic confirmation, clinicians should obtain tissue diagnosis from the primary tumor or site of metastases when clinically feasible. (Clinical Principle)
2. Clinicians should discuss treatment options with advanced prostate cancer patients based on life expectancy, comorbidities, preferences, and tumor characteristics. Patient care should incorporate a multidisciplinary approach when available. (*Clinical Principle*)

3. Clinicians should optimize pain control or other symptom support in advanced prostate cancer patients and encourage engagement with professional or community-based resources, including patient advocacy groups. (*Clinical Principle*)

**BIOCHEMICAL RECURRENCE WITHOUT METASTATIC DISEASE AFTER EXHAUSTION OF LOCAL TREATMENT OPTIONS**

**Prognosis**

4. Clinicians should inform patients with PSA recurrence after exhaustion of local therapy regarding the risk of developing metastatic disease and follow such patients with serial PSA measurements and clinical evaluation. Clinicians may consider radiographic assessments based on overall PSA and PSA kinetics. (*Clinical Principle*)

5. In patients with PSA recurrence after failure of local therapy who are at higher risk for the development of metastases (e.g., PSADT <12 months), clinicians should perform periodic staging evaluations consisting of cross-sectional imaging (CT, MRI) and technetium bone scan, and/or preferably PSMA PET imaging. (*Clinical Principle*)

6. Clinicians should utilize PSMA PET imaging preferentially, where available, in patients with PSA recurrence after failure of local therapy as an alternative to conventional imaging due to its greater sensitivity, or in the setting of negative conventional imaging. (*Expert Opinion*)

**Treatment**

7. For patients with a rising PSA after failure of local therapy and no demonstrated metastatic disease by imaging, clinicians should offer observation or clinical trial enrollment. (*Clinical Principle*)

8. ADT should not be routinely initiated in this population (*Expert Opinion*). However, if ADT is initiated in the absence of metastatic disease, intermittent ADT may be offered in lieu of continuous ADT. (*Conditional Recommendation; Evidence Level: Grade B*)

**METASTATIC HORMONE-SENSITIVE PROSTATE CANCER**

**Prognosis**

9. Clinicians should assess the extent of metastatic disease (lymph node, bone, and visceral metastases) in newly diagnosed mHSPC patients. (*Clinical Principle*)

10. In newly diagnosed mHSPC patients, clinicians should assess the extent of metastatic disease (low- versus high-volume). High-volume is defined as greater than or equal to four bone metastases with at least one metastasis outside of the spine/pelvis and/or the presence of visceral metastases. (*Moderate Recommendation: Evidence Level: Grade B*)

11. Clinicians should assess if a newly diagnosed mHSPC patient is experiencing symptoms from metastatic disease at the time of presentation to guide discussions of prognosis and further disease management. (*Moderate Recommendation; Evidence Level: Grade B*)
12. Clinicians should obtain a baseline PSA and serial PSAs at three- to six-month intervals after initiation of ADT in mHSPC patients and consider periodic conventional imaging. (*Clinical Principle*)

13. In patients with mHSPC, clinicians should offer germline testing, and consider somatic testing and genetic counseling. (*Clinical Principle*)

**Treatment**

14. Clinicians should offer ADT with either LHRH agonists or antagonists or surgical castration in patients with mHSPC. (*Strong Recommendation; Evidence Level: Grade B*)

15. In patients with mHSPC, clinicians should offer ADT in combination with either androgen pathway directed therapy (abiraterone acetate plus prednisone, apalutamide, enzalutamide) or chemotherapy (docetaxel). (*Strong Recommendation; Evidence Level: Grade A*)

16. In selected patients with de novo mHSPC, clinicians should offer ADT in combination with docetaxel and either abiraterone acetate plus prednisone or darolutamide. (*Strong Recommendation; Evidence Level: [Abiraterone] Grade A/[Darolutamide] Grade B*)

17. In selected mHSPC patients with low-volume metastatic disease, clinicians may offer primary radiotherapy to the prostate in combination with ADT. (*Conditional Recommendation; Evidence Level: Grade C*)

18. Clinicians should not offer first generation antiandrogens (bicalutamide, flutamide, nilutamide) in combination with LHRH agonists in patients with mHSPC, except to block testosterone flare. (*Strong Recommendation; Evidence Level: Grade A*)

19. Clinicians should not offer oral androgen pathway directed therapy (e.g., abiraterone acetate plus prednisone, apalutamide, bicalutamide, darolutomide, enzalutamide, flutamide, nilutamide) without ADT for patients with mHSPC. (*Expert Opinion*)

**NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER**

**Prognosis**

20. In nmCRPC patients, clinicians should obtain serial PSA measurements at three- to six-month intervals, and calculate a PSADT starting at the time of development of castration-resistance. (*Clinical Principle*)

21. Clinicians should assess nmCRPC patients for development of metastatic disease using conventional or PSMA PET imaging at intervals of 6 to 12 months. (*Expert Opinion*)

**Treatment**

22. Clinicians should offer apalutamide, darolutamide, or enzalutamide with continued ADT to nmCRPC patients at high risk for developing metastatic disease (PSADT ≤10 months). (*Strong Recommendation; Evidence Level Grade A*)

23. Clinicians may recommend observation with continued ADT to nmCRPC patients, particularly those at lower risk (PSADT >10 months) for developing metastatic disease. (*Clinical Principle*)

24. Clinicians should not offer systemic chemotherapy or immunotherapy to nmCRPC patients outside the context of a clinical trial. (*Clinical Principle*)
**METASTATIC CASTRATION-RESISTANT PROSTATE CANCER**

### Prognosis

25. In mCRPC patients, clinicians should obtain baseline labs (e.g., PSA, testosterone, LDH, Hgb, alkaline phosphatase level) and review location of metastatic disease (lymph node, bone, visceral), disease-related symptoms, and performance status to inform discussions of prognosis and treatment decision-making.  

*Clinical Principle*

26. In mCRPC patients without PSA progression or new symptoms, clinicians should perform imaging at least annually.  

*Expert Opinion*

27. In mCRPC patients with disease progression (PSA or radiographic progression or new disease-related symptoms) having previously received docetaxel and androgen pathway inhibitor, who are considering $^{177}$Lu-PSMA-617, clinicians should order PSMA PET imaging.  

*Expert Opinion*

28. In patients with mCRPC, clinicians should offer germline (if not already performed) and somatic genetic testing to identify DNA repair deficiency, microsatellite instability (MSI) status, tumor mutational burden, and other potential mutations that may inform prognosis and familial cancer risk, as well as direct potential targeted therapies.  

*Clinical Principle*

### Treatment

29. In newly diagnosed mCRPC patients, who have not received prior androgen receptor pathway inhibitors, clinicians should offer continued ADT with abiraterone acetate plus prednisone, docetaxel, or enzalutamide.  

*Strong Recommendation; Evidence Level: Grade A [abiraterone acetate plus prednisone and enzalutamide]/Grade B [docetaxel]*

30. In mCRPC patients who are asymptomatic or minimally symptomatic, clinicians may offer sipuleucel-T.  

*Conditional Recommendation; Evidence Level: Grade B*

31. Clinicians should offer radium-223 to patients with symptoms from bony metastases from mCRPC and without known visceral disease or lymphadenopathy >3cm.  

*Strong Recommendation; Evidence Level: Grade B*

32. Clinicians should offer $^{177}$Lu-PSMA-617 to patients with progressive mCRPC having previously received docetaxel and androgen pathway inhibitor with a positive PSMA PET imaging study.  

*Strong Recommendation; Evidence Level Grade: B*

33. In mCRPC patients who received prior docetaxel chemotherapy with or without prior abiraterone acetate plus prednisone or enzalutamide for the treatment of CRPC, clinicians may offer cabazitaxel.  

*Conditional Recommendation; Evidence Level: Grade B*

34. In mCRPC patients who received prior docetaxel chemotherapy and abiraterone acetate plus prednisone or enzalutamide, clinicians should recommend cabazitaxel rather than an alternative androgen pathway directed therapy.  

*Strong Recommendation; Evidence Level: Grade B*

35. Clinicians should offer a PARP inhibitor to patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated mCRPC following prior treatment with enzalutamide or abiraterone acetate, and/or a taxane-based chemotherapy. Platinum-based chemotherapy may be offered as an alternative for patients who cannot use or obtain a PARP inhibitor.  

*Moderate Recommendation; Evidence Level: Grade C*
36. In patients with mismatch repair deficient or microsatellite instability-high (MSI-H) mCRPC, clinicians should offer pembrolizumab. (*Moderate Recommendation; Evidence Level: Grade C*)

**BONE HEALTH**

37. Clinicians should discuss the risk of osteoporosis associated with ADT and should assess the risk of fragility fracture in patients with advanced prostate cancer. (*Clinical Principle*)

38. Clinicians should recommend preventative treatment for fractures and skeletal-related events, including supplemental calcium, vitamin D, smoking cessation, and weight-bearing exercise, to advanced prostate cancer patients on ADT. (*Clinical Principle*)

39. In advanced prostate cancer patients at high fracture risk due to bone loss, clinicians should recommend preventative treatments with bisphosphonates or denosumab and referral to physicians who have familiarity with the management of osteoporosis when appropriate. (*Clinical Principle*)

40. Clinicians should prescribe a bone-protective agent (denosumab or zoledronic acid) for mCRPC patients with bony metastases to prevent skeletal-related events. (*Moderate Recommendation; Evidence Level: Grade B*)
INTRODUCTION

PURPOSE

Epidemiology

Prostate cancer is the most common solid organ malignancy for men in the United States (U.S.) and remains the second leading cause of cancer deaths for this population. Approximately 288,300 new diagnoses of prostate cancer and 34,700 deaths are estimated in the U.S. in 2023.¹ The incidence of prostate cancer is 70% higher in Black men as compared to White men for reasons that remain unclear.² Importantly, the incidence of advanced stage disease including metastatic hormone-sensitive prostate cancer (mHSPC) has been increasing by about 5% per year in recent years. Unfortunately, prostate cancer mortality among Black men is approximately double that of men in most other groups. This disproportionate impact of prostate cancer morbidity and mortality on Black men is an area of active investigation that includes new approaches to screening, access to care, and treatment considerations among these men.³ While metastatic prostate cancer remains a lethal disease, improvements in overall survival (OS) through combination therapies have resulted in a renaissance in the entire landscape for clinicians caring for men with advanced metastatic prostate cancer. Prostate cancer deaths are typically the result of progression to metastatic castration-resistant prostate cancer (mCRPC). Historically, the median survival for men with mCRPC was less than two years, but due to several factors including the impact of novel therapies, the median survival is now increasing with some men surviving beyond five years. ³ Furthermore, rapid therapeutic advances in the treatment landscape for mHSPC and mCRPC render treatment decisions and sequencing increasingly complex. Therefore, at present, there is limited data driven evidence regarding optimal agent combination or sequence. It is against this backdrop that the Panel provides evidence-based guidance for treatment of men with advanced prostate cancer and looks to the future with cautious optimism.

Justification for a New Guideline

Clinicians treating men with advanced prostate cancer are challenged with the rapidly evolving prostate cancer landscape given the approval of new classes of agents for use in various prostate cancer disease states. The increasing complexity of advanced prostate cancer management underscores the need for the current clinical practice guideline, developed to provide a rational basis for treatment of patients with advanced disease, based on currently available published data. To assist in clinical decision-making, guideline recommendations are furnished according to disease states across the entire continuum of advanced prostate cancer.

Disease States

This guideline covers advanced prostate cancer as defined by the five disease states outlined below. It should be noted that this guideline does not cover local therapy (see AUA Guideline on Clinically Localized Prostate Cancer).⁴ The patient population covered in this guideline is assumed to have already received local or pelvic therapy, including adjuvant and salvage therapy (e.g., exhaustion of local treatment options). Further, neuroendocrine tumors and small cell variants were considered outside the scope of this guideline.

BIOCHEMICAL RECURRENCE (“RISING PSA STATE”) WITHOUT METASTATIC DISEASE AFTER EXHAUSTION OF LOCAL TREATMENT OPTIONS

After local therapy including surgery or radiation, the first sign of recurrence is typically a rising PSA in the absence of visible metastases. This is also assuming that all forms of local therapy (e.g., salvage radiotherapy after radical prostatectomy, or salvage prostatectomy/salvage local ablative therapy after external beam radiotherapy [EBRT]) have been exhausted. Patients understand that their local treatment has not eradicated the cancer because of continued rises in PSA. Management of this disease state is controversial as evidence is lacking for optimal treatment approaches.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER

mHSPC has been increasingly diagnosed since 2013, likely due to multiple factors including greater imaging sensitivity and changes to PSA screening guidelines, amongst other reasons. In addition to being increasingly common, mHSPC and treatment of this disease state has shifted greatly since the first studies (CHAARTED and STAMPEDE) testing up-front docetaxel were reported.
beginning in 2014.\textsuperscript{5,6} Metastatic hormone-sensitive disease can occur due to recurrence after initial local therapy for localized prostate cancer or as de novo metastatic disease, a distinction that may be useful when deciding upon systemic therapy. Additionally, the volume and site of metastatic disease are important factors that can affect prognosis and treatment choice.

**Castration-resistant Prostate Cancer**

Castration-resistant prostate cancer (CRPC), whether metastatic (mCRPC) or non-metastatic (nmCRPC), generally occurs in response to therapeutic pressure, specifically the use of androgen deprivation therapy (ADT). The exact mechanism of transition from hormone-sensitive to castration-resistant disease is still not fully understood, and some diseases may be inherently resistant at presentation. However, it is clear that despite castrate levels of androgens, the androgen receptor (AR) remains active and continues to drive prostate cancer progression in most cancers.\textsuperscript{7,8} Because of this, multiple agents have been developed that further decrease androgen production or block AR signaling in addition to standard ADT with luteinizing hormone-releasing hormone (LHRH) agonists or antagonists. It is hypothesized that there are additional biologic pathways that function independently of androgen signaling resulting in CRPC. With a greater understanding of tumor biology, there is hope for continued development of innovative treatment options that further improve survival for men with CRPC.

**Non-metastatic Castration-resistant Prostate Cancer**

Men with a rising PSA but no visible metastatic disease on conventional imaging, despite medical or surgical castration, represent a uniquely distinct disease state. The advent of improved imaging including next generation positron emission tomography-computed tomography (PET-CT) scanning has allowed for the discovery of small volume metastases that were previously undetected with standard clinical imaging such as bone scans, CT, and magnetic resonance imaging (MRI). Nevertheless, there remains a subset of patients whose disease remains defined by biochemical PSA rise only. Until recently, there have been no agents specifically FDA approved for the treatment of men with nmCRPC. However, three AR antagonists successfully prolonged metastasis-free survival (MFS), defined as the development of metastases or death from any cause, when compared with ADT plus placebo in men with nmCRPC.\textsuperscript{9-11}

The use of MFS rather than OS as a regulatory endpoint is novel in solid tumors, and was partially based on the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) meta-analysis of 19 clinical trials demonstrating that MFS is a surrogate for OS in men with localized prostate cancer.\textsuperscript{12} Additionally, recent press releases state that two of the three approved AR antagonists also improve OS in this population.\textsuperscript{13,14} Data from the third study continues to mature.

**Metastatic Castration-resistant Prostate Cancer**

The treatment of men with mCRPC has dramatically changed over the past decade. Prior to 2004, once primary androgen deprivation failed to control the disease, treatments were administered solely for palliation. Landmark studies by Tannock et al. and Petrylak et al. demonstrated that docetaxel improved survival and quality of life (QOL) for such patients with mCRPC.\textsuperscript{15,16} Since the approval of docetaxel, multiple additional agents that show a survival benefit have been FDA-approved on the basis of randomized controlled trials (RCTs).\textsuperscript{17-21} These agents have been tested in multiple “disease states” of mCRPC, both before and after docetaxel chemotherapy, to determine when patients might benefit from each treatment.

**Terminology and Definitions**

There are several key terms and definitions that should be considered when interpreting this guideline. First, biochemical recurrence is a rise in PSA in prostate cancer patients after treatment with surgery or radiation (PSA of 0.2ng/mL and a confirmatory value of 0.2ng/mL or greater following radical prostatectomy and nadir + 2.0ng/mL following radiation). This may occur in patients who do not have symptoms. HSPC refers to prostate cancer that has either not yet been treated with ADT or is still responsive to ADT as manifested by the absence of clinical progression, radiographic progression, or a rising PSA of ≥2.0ng/mL above nadir. This may also be referred to as castrate-sensitive prostate cancer, endocrine-sensitive prostate cancer, and hormone-naïve prostate cancer. CRPC is defined by disease progression despite ADT and a castrate level of testosterone (<50ng/dL). Contemporary lab testing indicates that testosterone...
levels decline to <20ng/dL after orchiectomy.\textsuperscript{22} Progression may present as either a continuous rise in serum (PSA) levels (values identified at a minimum of 1 week intervals with a minimal value of 2.0ng/mL, with estimations of PSA doubling time [PSADT] with at least 3 values measured ≥4 weeks apart), the progression of pre-existing or new radiographic disease, and/or clinical progression with symptoms.\textsuperscript{5} High-volume metastatic disease is used in the mHSPC setting, and is defined per the CHAARTED definition of the presence of visceral metastases and/or greater than or equal to four bone metastases with at least one outside of the vertebral column and pelvis.\textsuperscript{5} Low-volume metastatic disease describes metastatic disease that does not meet high-volume criteria. These definitions can be useful when choosing treatment for mHSPC, particularly for radiation of the primary tumor, and are associated with better (low-volume) or poorer (high-volume) prognosis in the mHSPC disease state.\textsuperscript{5,23} High-risk metastatic disease is defined per the LATITUDE definition for mHSPC that has a poorer prognosis in the presence of 2 of the 3 following high-risk features: Gleason ≥ 8, ≥ 3 bone lesions, or measurable visceral metastases.\textsuperscript{24} De novo metastatic disease describes metastatic disease that is present at the time of initial prostate cancer diagnosis rather than recurring after previous treatment of localized cancer. This is associated with poorer prognosis than recurrent disease.\textsuperscript{25} PSA doubling time (PSADT) is the number of months required for the PSA value to increase two-fold.\textsuperscript{26} There are a number of web-based tools available to calculate PSADT, including that provided by Memorial Sloan Kettering Cancer Center available at https://www.mskcc.org/nomograms/prostate/psa_doubling_time. This tool also provides supporting text detailing the precise calculation of PSADT. Conventional imaging is defined as CT, MRI, and $^{99m}$Tc-methylene diphosphonate bone scan (bone scan). These terms are summarized in Table 1.

Table 1: Key Terminology

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disease States</strong></td>
<td></td>
</tr>
<tr>
<td>Biochemical recurrence without metastatic disease</td>
<td>• a rise in PSA in prostate cancer patients after treatment with surgery or radiation (PSA of 0.2ng/mL and a confirmatory value of 0.2ng/mL or greater following radical prostatectomy and nadir + 2.0ng/mL following radiation); this may occur in patients who do not have symptoms</td>
</tr>
<tr>
<td>Hormone-sensitive prostate cancer</td>
<td>• prostate cancer that has either not yet been treated with ADT or is still responsive to ADT</td>
</tr>
<tr>
<td>Castration-resistant prostate cancer</td>
<td>• disease progression despite ADT and a castrate level of testosterone (&lt;50ng/dL); progression may present as either a continuous rise in serum PSA levels (values identified at a minimum of 1-week intervals with a minimal value of 2.0ng/mL, with estimations of PSADT with at least 3 values measured ≥4 weeks apart), the progression of pre-existing or new radiographic disease, and/or clinical progression with symptoms</td>
</tr>
<tr>
<td>High-volume metastatic disease</td>
<td>• presence of visceral metastases and/or greater than or equal to four bone metastases with at least one outside of the vertebral column and pelvis</td>
</tr>
<tr>
<td>High-risk metastatic disease</td>
<td>• disease that has a poorer prognosis in the presence of two of the three following high-risk features: Gleason ≥8, ≥3 bone lesions, or measurable visceral metastases</td>
</tr>
<tr>
<td>De novo metastatic disease</td>
<td>• metastatic disease that is present at the time of initial prostate cancer diagnosis rather than recurring after previous treatment of localized cancer</td>
</tr>
<tr>
<td><strong>Disease Management</strong></td>
<td></td>
</tr>
<tr>
<td>PSA doubling time</td>
<td>• the number of months required for the PSA value to increase two-fold</td>
</tr>
<tr>
<td>Conventional imaging</td>
<td>• computed tomography, magnetic resonance imaging, and $^{99m}$Tc-methylene diphosphonate bone scan</td>
</tr>
</tbody>
</table>
Radiologic Considerations

The prostate cancer community has witnessed considerable developments in the detection of disease with next generation prostate cancer imaging. PET-CT has emerged as a sensitive and specific imaging test to detect prostate cancer metastases, particularly among men with biochemical recurrence after primary therapy.27, 28 Multiple PET tracers have demonstrated promise in the evaluation of extent of prostate cancer including 18F-fluciclovine, 18F-sodium fluoride, 11C-choline, and various tagged prostate-specific membrane antigen (PSMA) isoforms. While there is an emerging literature detailing the use of next generation imaging to guide management decisions in recurrent prostate cancer,29,30 there remains uncertainty about how these image-directed therapies will impact oncologic outcomes.

It is important for the practicing clinician to note that the studies underpinning this guideline’s recommendations were largely predicated upon the use of conventional imaging including CT, MRI, and bone scan. As the medical evidence evolves to more consistently incorporate next generation imaging, the definition of “non-metastatic” and “metastatic” will evolve owing to the significant differences in sensitivity to detect metastatic disease between conventional and advanced imaging modalities. Nonetheless, for the purpose of this guideline, the practicing clinician should consider “metastatic” disease that which is identified on conventional imaging.

Multidisciplinary Nature of Treatment in Today’s Advanced Prostate Cancer Care Paradigm

As the therapeutic landscape evolves to include increasing complex combinations of systemic therapies with or without local therapies, advances in imaging, and germline and somatic genetic testing, treating men with advanced prostate cancer is increasingly one that must embrace multidisciplinary management approaches. Team members should include urologists, medical oncologists, and radiation oncologists at a minimum when supporting treatment decisions for advanced disease. Additional specialists may also include genitourinary pathology, genetic counseling, palliative care, and holistic specialists, as appropriate, in addition to primary care. Best practices must also include clinicians comfortable describing the use of germline and somatic genetic testing, and when advanced imaging techniques could be optimally used or avoided. Radiologists and nuclear medicine specialists are valuable in helping to accurately interpret scans. Palliative care team members may also play a key role when treating men with symptomatic metastatic disease. Palliative care itself is an interdisciplinary, holistic approach to managing an advanced disease such as prostate cancer with a guarded prognosis. It can include controlling symptoms that are physical, psychological, spiritual, and social. The goal of palliation is to prevent and relieve suffering and to support the best possible QOL for the patient and family.

Performance Status and Predicted Life Expectancy

Performance status and predicted life expectancy are both critical elements to incorporate into individualized clinical decision-making in men with advanced prostate cancer. Performance status remains a key factor in treatment decision-making, particularly among men with advanced prostate cancer. Indeed, performance status has been found to be strongly associated with survival among men with mCRPC,31-34 and has been used to define index patients in prior versions of this guideline. Performance status generally describes an individual patient’s level of functioning and how one’s disease impacts a patient’s activities of daily living. The first of two commonly used scales to evaluate performance status include the Eastern Cooperative Oncology Group (ECOG) scale from 0 to 5 where 0 is fully functional and 5 is dead. The second is the Karnofsky scale where 10 represents a moribund individual and 100 represents an individual with no limitations.

It is important to acknowledge that clinical trials have generally excluded patients with a poor performance status from participation. Thus, most data regarding management of patients with limited performance status are extrapolated from randomized trials of eligible patients who had a better performance status, as well as from some smaller trials and registries. Incorporating performance status into shared treatment decision-making permits the treating clinician and patient to characterize the balance of risk and benefit associated with sometimes morbid treatments. While performance status is frequently used to predict an individual patient’s likelihood of tolerating a particular cancer treatment, it is
equally important to consider the likelihood that a particular treatment improves disease-related symptoms and drives meaningful improvement in performance status.

Thoughtful assessment of performance status and life expectancy are essential components of evaluation and management of men with advanced prostate cancer. Indeed, assessment of performance status and life expectancy are core to establishing goals of care, incorporating individuals' values and preferences to best align available management options with what is most important to patients and their families. While performance status is no longer included in the classification of disease states in this guideline, ongoing assessment of performance status is considered a necessary component of continuing care that will help the patient and clinician guide the cascade of management for advanced prostate cancer.

**Clinical Trial Enrollment**

Clinicians should inform patients about suitable clinical trials and encourage patients to consider participation in such trials based on eligibility and access. Treatment options can be characterized as standard and as investigational (clinical trial). In general, standard therapies have proven efficacy and risks determined by prospective trials. There are many types of clinical trials including trials evaluating novel systemic, surgical, or radiation therapies; new approaches to approved therapies; device trials; and trials focusing on QOL and other patient outcomes. All clinical trials include specified aim(s) with a predetermined statistical plan. Institutional Review Boards approve all clinical trials and patient consent forms, and all patients must sign consent for trial participation.

In appropriate patients, clinical trial options should be considered, and trial options should be discussed with patients as part of the shared decision-making process. Clinical trials are listed by diagnosis and stage on the Clinicaltrials.gov website.

**METHODOLOGY**

The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. Determination of the guideline scope and review of the final systematic review to inform guideline statements was conducted in conjunction with the Advanced Prostate Cancer Panel.

**Panel Formation**

The Panel was created in 2018 by the American Urological Association Education and Research, Inc. (AUAER). This guideline was developed in collaboration with the American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) with additional panel representation from the American Society of Clinical Oncology (ASCO). The Practice Guidelines Committee (PGC) of the AUA selected the Panel Chair and Vice Chair who in turn appointed the additional panel members with specific expertise in this area in conjunction with ASTRO, SUO, and ASCO. Additionally, the Panel included patient representation. Funding of the Panel was provided by the AUA; panel members received no remuneration for their work.

The Advanced Prostate Cancer Amendment Panel was created in 2022 by the AUA to review new literature and provide updates herein. The panel members received no remuneration for their work.

**Searches and Article Selection**

A research librarian conducted searches in Ovid MEDLINE (1998 to January Week 5 2019), Cochrane Central Register of Controlled Trials (through December 2018), and Cochrane Database of Systematic Reviews (2005 through February 6, 2019). An updated search was conducted prior to publication through January 20, 2020. The methodology team supplemented searches of electronic databases with the studies included in the prior AUA review and by reviewing reference lists of relevant articles.

The methodology team developed criteria for inclusion and exclusion of studies based on the Key Questions and the populations, interventions, comparators, outcomes, and settings (PICOTS) of interest. The population was patients with advanced prostate cancer as described in Table 1. Treatments included first and second line antiandrogens, immunotherapy, chemotherapy, radiation therapy, surgery, radiopharmaceuticals, and surveillance strategies. Comparisons were against placebo, no therapy or another active intervention, and intermittent versus continuous therapy. Outcomes included OS,
prostate cancer mortality, progression-free survival (PFS), prostate-specific antigen progression-free survival (PSA-PFS), failure-free survival, metastases-free survival, time to metastases, time to progression, skeletal events, and adverse events.

For evaluation of treatments, inclusion was restricted to randomized trials, with the exception of studies on sequencing of therapies for which cohort studies were also included. For evaluation of prognostic factors, the methodology team included primary studies and systematic reviews that reported hazard ratios (HR) or the area under the receiver operating characteristic curve (AUROC), a measure of discrimination. We excluded non-randomized studies of interventions and case reports, narrative reviews, case-control studies, and non-English language articles. We also excluded in vitro and animal studies. Articles were published in peer-reviewed journals in or after 1998, though the methodology team included studies published prior to 1998 that were identified from reference lists.

Using the pre-specified criteria, two investigators independently reviewed titles and abstracts of all citations. The methodology team used a two-phase method for screening full-text articles identified during review of titles and abstracts. In the first phase, methodologists reviewed full-text articles to identify relevant systematic reviews for inclusion. Methodologists selected systematic reviews that addressed Key Questions, were higher quality, and were published within the last five years. The second phase reviewed full-text articles to identify primary studies for key questions not sufficiently answered by previously published systematic reviews and new studies published subsequent to the systematic reviews.

Database searches resulted in 10,517 potentially relevant articles of which 918 were selected for full-text review; 230 publications met inclusion criteria and were included in this review. Forty-six studies were carried over from the prior AUA review.

**Data Abstraction**

For primary studies that met inclusion criteria, a single investigator abstracted information on study design, year, setting, country, sample size, eligibility criteria, dose and duration of the intervention, population characteristics (age, race, tumor stage, performance status, PSA level, prior treatments, type and extent of metastatic disease), results, and source of funding. For systematic reviews, investigators abstracted characteristics of the included studies (number, design and sample sizes of included studies, study settings), population characteristics (inclusion and exclusion criteria), interventions, methods and ratings for the risk of bias of included studies, synthesis methods, and results. For OS and PFS, HR estimates were based on the number of deaths or number of deaths or cases of progression, so that estimates <1 indicate improved survival. Data abstractions were reviewed by a second investigator for accuracy, and discrepancies were resolved through discussion and consensus.

**Risk of Bias Assessment**

Two investigators independently assessed risk of bias using predefined criteria. Disagreements were resolved by consensus. For randomized trials and cohort studies, methodologists adapted criteria for assessing risk of bias from the U.S. Preventive Services Task Force. Criteria for randomized trials included use of appropriate randomization and allocation concealment methods, baseline comparability of groups, blinding, attrition, and use of intention-to-treat analysis. For cohort studies on prognostic factors, criteria included methods for assembling cohorts, attrition, blinding assessment of outcomes, and adjustment for potential confounding.

The methodology team assessed systematic reviews using Assessing the Methodological Quality of Systematic Reviews (AMSTAR 2) criteria. Criteria included use of pre-specified methods, appropriate search methods, assessment of risk of bias, and appropriate synthesis methods. Studies were rated as “low risk of bias,” “medium risk of bias,” or “high risk of bias” based on the presence and seriousness of methodological shortcomings.

Studies rated “low risk of bias” are generally considered valid. “Low risk of bias” randomized trials include clear descriptions of the population, setting, interventions, and comparison groups; a valid method for allocation of patients to treatment; low dropout rates (defined as >20%, not counting those who died or met other endpoints) and clear reporting of dropouts; blinding of patients, care providers, and outcome assessors; and appropriate analysis of outcomes.
Studies rated “medium risk of bias” are susceptible to some bias, though not necessarily enough to invalidate the results. These studies do not meet all the criteria for a rating of low risk of bias, but no flaw is likely to cause major bias. Studies may be missing information, making it difficult to assess limitations and potential problems. The “medium risk of bias” category is broad, and studies with this rating vary in their strengths and weaknesses. Therefore, the results of some medium risk of bias studies are likely to be valid, while others may be only possibly valid.

Studies rated “high risk of bias” have significant flaws that may invalidate the results. They have a serious or “fatal” flaw in design, analysis, or reporting; large amounts of missing information; discrepancies in reporting; or serious problems in the delivery of the intervention. The results of high risk of bias studies could be as likely to reflect flaws in study design and conduct as true difference between compared interventions. The methodology team did not exclude studies rated high risk of bias a priori, but high risk of bias studies were considered to be less reliable than low or medium risk of bias studies, and the methodology team performed sensitivity analyses without high risk of bias studies to determine how their inclusion impacted findings.

**Data Synthesis**

The methodology team constructed evidence tables with study characteristics, results, and risk of bias ratings for all included studies, and summary tables to highlight the main findings. The methodology team reported pooled estimates and other results from systematic reviews and examined whether the findings of new studies were consistent with the reviews.

The methodology team graded the strength of evidence for interventions using the approach described in the AHRQ EPC Methods Guide for Comparative Effectiveness and Effectiveness Reviews. For strength of evidence assessments, methodologists focused on the outcomes OS and PFS and key treatment comparisons. Strength of evidence assessments were based on the following domains:

- Study limitations, based on the overall risk of bias across studies (low, medium, or high) and the seriousness of methodological limitations
- Consistency of results across studies (consistent, inconsistent, or unable to determine when only one study was available)
- Directness of the evidence linking the intervention and health outcomes (direct or indirect)
- Precision of the estimate of effect, based on the number and size of studies and confidence intervals for the estimates (precise or imprecise)
- Reporting bias, based on whether the studies defined and reported primary outcomes and whether we identified relevant unpublished studies (suspected or undetected)

**Determination of Evidence Strength**

Based on assessments of the domains described above, the methodology team graded the strength of evidence for each intervention as high, moderate, low, or very low. RCTs of interventions start as “high” strength of evidence and are graded down based on the presence and severity of shortcomings in each domain. A “high” grade indicates high confidence that the evidence reflects the true effect and that further research is very unlikely to change confidence in the estimate of effect. A “moderate” grade indicates moderate confidence that the evidence reflects the true effect and further research may change the estimate. A “low” grade indicates low confidence that the evidence reflects the true effect and further research is likely to change the confidence in the estimate of effect and could increase the confidence in the estimate. A “very low” grade indicates evidence either is unavailable or is too limited to permit any conclusion due to extreme study limitations, inconsistency, imprecision, or reporting bias.

The AUA employs a three-tiered strength of evidence system to underpin evidence-based guideline statements. In short, high certainty by GRADE translates to AUA A-category strength of evidence, moderate to B, and both low and very low to C. (Table 2)

The AUA categorizes body of evidence strength as Grade A (e.g., well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings), Grade B (e.g., RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings), or Grade C (e.g., RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially
confound interpretation of data). By definition, Grade A evidence is evidence about which the Panel has a high level of certainty, Grade B evidence is evidence about which the Panel has a moderate level of certainty, and Grade C evidence is evidence about which the Panel has a low level of certainty.  

Table 2: Strength of Evidence Definitions

<table>
<thead>
<tr>
<th>AUA Strength of Evidence Category</th>
<th>GRADE Certainty Rating</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>High</td>
<td>• Very confident that the true effect lies close to that of the estimate of the effect</td>
</tr>
</tbody>
</table>
| B                                 | Moderate               | • Moderately confident in the effect estimate  
|                                   |                        | • The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different |
| C                                 | Low                    | • Confidence in the effect estimate is limited  
|                                   | Very Low               | • The true effect may be substantially different from the estimate of the effect  
|                                   |                        | • Very little confidence in the effect estimate  
|                                   |                        | • The true effect is likely to be substantially different from the estimate of effect |

**AUA Nomenclature: Linking Statement Type to Evidence Strength**

The AUA nomenclature system explicitly links statement type to body of evidence strength, level of certainty, magnitude of benefit or risk/burdens, and the Panel’s judgment regarding the balance between benefits and risks/burdens (Table 3). Strong Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is substantial. Moderate Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is moderate. Conditional Recommendations are non-directive statements used when the evidence indicates that there is no apparent net benefit or harm, when benefits and harms are finely balanced, or when the balance between benefits and risks/burden is unclear. All three statement types may be supported by any body of evidence strength grade. Body of evidence strength Grade B in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most patients in most circumstances but that better evidence could change confidence. Body of evidence strength Grade C in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most patients in most circumstances but that better evidence is likely to change confidence. Conditional Recommendations also can be supported by any evidence strength. When body of evidence strength is Grade A, the statement indicates that benefits and risks/burdens appear balanced, the best action depends on patient circumstances, and future research is unlikely to change confidence. When body of evidence strength Grade B is used, benefits and risks/burdens appear balanced, the best action also depends on individual patient circumstances and better evidence could change confidence. When body of evidence strength Grade C is used, there is uncertainty regarding the balance between benefits and risks/burdens; therefore, alternative strategies may be equally reasonable, and better evidence is likely to change confidence.
Table 3: AUA Nomenclature Linking Statement Type to Level of Certainty, Magnitude of Benefit or Risk/Burden, and Body of Evidence Strength

<table>
<thead>
<tr>
<th>Evidence Grade</th>
<th>Evidence Strength A (High Certainty)</th>
<th>Evidence Strength B (Moderate Certainty)</th>
<th>Evidence Strength C (Low Certainty)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong Recommendation (Net benefit or harm substantial)</td>
<td>- Benefits &gt; Risks/Burdens (or vice versa) - Net benefit (or net harm) is substantial - Applies to most patients in most circumstances and future research is unlikely to change confidence</td>
<td>- Benefits &gt; Risks/Burdens (or vice versa) - Net benefit (or net harm) is substantial - Applies to most patients in most circumstances but better evidence could change confidence</td>
<td>- Benefits &gt; Risks/Burdens (or vice versa) - Net benefit (or net harm) appears substantial - Applies to most patients in most circumstances but better evidence is likely to change confidence (rarely used to support a Strong Recommendation)</td>
</tr>
<tr>
<td>Moderate Recommendation (Net benefit or harm moderate)</td>
<td>- Benefits &gt; Risks/Burdens (or vice versa) - Net benefit (or net harm) is moderate - Applies to most patients in most circumstances and future research is unlikely to change confidence</td>
<td>- Benefits &gt; Risks/Burdens (or vice versa) - Net benefit (or net harm) is moderate - Applies to most patients in most circumstances but better evidence could change confidence</td>
<td>- Benefits &gt; Risks/Burdens (or vice versa) - Net benefit (or net harm) appears moderate - Applies to most patients in most circumstances but better evidence is likely to change confidence</td>
</tr>
<tr>
<td>Conditional Recommendation (Net benefit or harm comparable to other options)</td>
<td>- Benefits=Risks/Burdens - Best action depends on individual patient circumstances - Future Research is unlikely to change confidence</td>
<td>- Benefits=Risks/Burdens - Best action appears to depend on individual patient circumstances - Better evidence could change confidence</td>
<td>- Balance between Benefits &amp; Risks/Burdens unclear - Net benefit (or net harm) comparable to other options - Alternative strategies may be equally reasonable - Better evidence likely to change confidence</td>
</tr>
<tr>
<td>Clinical Principle</td>
<td>a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expert Opinion</td>
<td>a statement, achieved by consensus of the Panel, that is based on members' clinical training, experience, knowledge, and judgment for which there may or may not be evidence in the medical literature</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Where gaps in the evidence existed, the Panel provides guidance in the form of Clinical Principles or Expert Opinions with consensus achieved using a modified Delphi technique if differences of opinion emerged. A Clinical Principle is a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature. Expert Opinion refers to a statement, achieved by consensus of the Panel, that is based on members’ clinical training, experience, knowledge, and judgment for which there may or may not be evidence.

Peer Review and Document Approval

An integral part of the guideline development process at the AUA is external peer review. The AUA conducted a thorough peer review process to ensure that the document was reviewed by experts in the diagnosis and management of Advanced Prostate Cancer. In addition to reviewers from the AUA PGC, Science and Quality Council (SQC), and Board of Directors (BOD), the document was reviewed by representatives from ASTRO, SUO, and ASCO as well as external content experts. Additionally, a call for reviewers was placed on the AUA website from December 2-16, 2019 to allow any additional interested parties to request a copy of the document for review. The guideline was also sent to the Urology Care Foundation and representation from prostate cancer advocacy to open the document further to the patient perspective. The draft guideline document was distributed to 96 peer reviewers. All peer review comments were blinded and sent to the Panel for review. In total, 44 reviewers provided comments, including 34 external reviewers. At the end of the peer review process, a total of 522 comments were received. Following comment discussion, the Panel revised the draft as needed. Once finalized, the guideline was submitted for approval to the AUA PGC, SQC, and BOD as well as SUO.

The Advanced Prostate Cancer Amendment Panel was created in 2022 to review new literature and provide updates to this guideline, where appropriate. As a result of amendments to this guideline, a thorough peer review process was conducted in the same manner as with the original publication. A call for peer reviewers was posted December 2022. The draft guideline was distributed to 89 peer reviewers, 38 of whom submitted comments. The Amendment Panel reviewed and discussed all submitted comments and revised the draft as needed. Once finalized, the guideline was submitted for approval to the PGC, SQC, and BOD as well as SUO.

Guideline Statements

EARLY EVALUATION AND COUNSELING

1. In patients with suspicion of advanced prostate cancer and no prior histologic confirmation, clinicians should obtain tissue diagnosis from the primary tumor or site of metastases when clinically feasible. (Clinical Principle)

Patients with clinical signs and symptoms suggestive of advanced prostate cancer should undergo a biopsy to obtain histologic confirmation at the time of diagnosis and at later dates, if needed. While biopsy of the metastatic deposit may be optimal, biopsy of the primary tumor may be all that is available. Although the clinical picture is often consistent with the diagnosis, subsequent treatment may strongly depend on histologic and molecular features of the malignancy. For example, poly (ADP-ribose) polymerase (PARP) inhibitors and PD-1/PD-L1 inhibitors require the identification of mutations in DNA repair genes and evidence of mismatch repair (MMR) gene defects leading to MSI, respectively. Further, biopsy may reveal evidence of neuroendocrine differentiation. Additional treatments will be developed in the coming years that are biomarker-dependent. After treatment with standard ADT, the opportunity to obtain tissue may be delayed or lost. This recommendation comes with the caveat that patient safety always comes first, and if the patient cannot tolerate biopsy or if there is no accessible tissue, treatment may proceed in the absence of histological confirmation. A biopsy may be obtained later as the patient’s clinical condition improves.

2. Clinicians should discuss treatment options with advanced prostate cancer patients based on life expectancy, comorbidities, preferences, and tumor characteristics. Patient care should incorporate a multidisciplinary approach when available. (Clinical Principle)
Prostate cancer patients frequently have comorbid conditions that may impact life expectancy as well as the ability to tolerate prostate cancer-directed therapies. Additionally, the patient’s personal goals of care must be carefully considered when making management recommendations. For older patients or those with multiple comorbidities, a formal geriatric or medical assessment may provide assistance for the clinician in making management recommendations.

In the Panel’s judgment, relevant input into these complex issues may be best obtained by the involvement of a number of prostate cancer experts (e.g., urology, medical oncology, palliative medicine, radiation oncology, mental health professionals) in addition to the patient’s primary care provider in the care of patients with advanced prostate cancer.

3. Clinicians should optimize pain control or other symptom support in advanced prostate cancer patients and encourage engagement with professional or community-based resources, including patient advocacy groups. (Clinical Principle)

While the focus on care for patients with metastatic disease is improving survival, management of patients' symptoms and QOL are of great concern to patients and their families. As such, physicians caring for patients with advanced disease should manage symptoms such as pain, urinary symptoms, and sexual function, as well as side-effects of treatment. In addition, providers should avail themselves of resources in the community such as in-person and online support groups, palliative care professionals, and mental health professionals who can provide additional support and improve QOL.

BIOCHEMICAL RECURRENCE WITHOUT METASTATIC DISEASE AFTER EXHAUSTION OF LOCAL TREATMENT OPTIONS

Prognosis

4. Clinicians should inform patients with PSA recurrence after exhaustion of local therapy regarding the risk of developing metastatic disease and follow such patients with serial PSA measurements and clinical evaluation. Clinicians may consider radiographic assessments based on overall PSA and PSA kinetics. (Clinical Principle)

In the hormone-sensitive setting, PSA recurrence almost always precedes clinical detection of metastases. However, given the indolent nature of some cancers, not all patients with a detectable PSA following primary treatment are destined to experience clinical recurrence or cancer-related death. The incidence of PSA recurrence after primary radical prostatectomy or radiotherapy varies depending on clinical and pathologic risk factors, such as tumor grade, stage, and pre-treatment PSA.

A systematic review and meta-analysis showed that many of the risk factors for PSA recurrence (grade, stage, and pre-treatment PSA) were also prognostic factors for those who experience clinical recurrence. In addition, time to PSA recurrence and PSADT were also associated with risk of subsequent metastases, prostate cancer-related death, and death from any cause. The authors of the systematic review proposed dichotomizing a patient’s risk of metastases based on the most robust risk factors available in the literature. For patients with PSA recurrence after radical prostatectomy, International Society of Urologic Pathologists (ISUP) grade group 4/5 (Gleason ≥8) or PSADT ≤1 year were considered high-risk for development of metastases and death. For patients with PSA recurrence after prostate radiation, those with biopsy ISUP grade group 4/5 (Gleason ≥8) and/or those with ≤18 months to PSA failure are at highest risk. Patients who do not meet one of the criteria above are considered lower risk of developing clinical metastases.
The proposed risk stratification was recently applied to a European cohort of patients treated with radical prostatectomy. In this analysis, the 5-year estimated freedom from metastases was 97.5% (95% CI: 95.8% to 99.1%) for the low-risk cohort and 86.7% (95% CI: 83.4% to 90.1%) for the high-risk cohort. Unfortunately, the discriminative accuracy was only 67% to predict metastases and 69% to predict prostate cancer-related death. Therefore, more work needs to be done to improve prognostication for patients with PSA recurrence, and the proposed risk strata have not yet been validated in a cohort treated with primary radiation.

Despite the limitations of risk assessment, it is clear that several factors predict future recurrence and that this information should be provided to patients. Since PSA kinetics contribute to the risk of clinical recurrence, serial PSA measurements and evaluations are necessary for patients who develop PSA recurrence after local therapy.

5. In patients with PSA recurrence after failure of local therapy who are at higher risk for the development of metastases (e.g., PSADT <12 months), clinicians should perform periodic staging evaluations consisting of cross-sectional imaging (CT, MRI) and technetium bone scan, and/or preferably PSMA PET imaging. (Clinical Principle)

Cross-sectional imaging with CT or MRI along with \(^{99m}\)Tc-methylene diphosphonate bone scintigraphy have been the standard imaging approaches for post-treatment biochemical recurrence. The primary rationale for utilizing these approaches relates to the fact that current standard of care (SOC) systemic treatments in mHSPC are based on such conventional imaging approaches rather than advanced/molecular imaging (e.g., CHAARTED, STAMPEDE, LATITUDE). It should be noted, however, that these modalities infrequently detect metastases in the setting of early PSA recurrence (e.g., PSA <5ng/mL). For example, Kane et al. reported that only 14% of patients in a biochemical recurrence cohort had positive CT scans and 9.4% had positive bone scans, with these patients generally having high PSAs and/or rapid PSA kinetics. Only 4.5% of patients with a PSA <10ng/mL had a positive bone scan. Odewole et al. reported on a cohort of patients undergoing both CT and \(^{18}\)F-fluciclovine PET for biochemical recurrence, and found that 6 of 29 patients (20.7%) with a PSA ≤5ng/mL had a positive CT finding. In another study, the CT detection rate was 17% for patients with a PSA ≤4ng/mL. Novel imaging techniques have evolved, and there are now two FDA approved PSMA PET agents for patients with advanced prostate cancer (\(^{68}\)Ga-PSMA-11 and Piflufolastat F-18 \(^{18}\)F-DCFPyL), including patients with suspected recurrence based on rising PSA levels, which demonstrate greater sensitivity than conventional imaging. These agents are further discussed in statement 6.

6. Clinicians should utilize PSMA PET imaging preferentially, where available, in patients with PSA recurrence after failure of local therapy as an alternative to conventional imaging due to its greater sensitivity, or in the setting of negative conventional imaging. (Expert Opinion)

PET tracers show greater sensitivity than conventional imaging for the detection of prostate cancer recurrence and metastases at low PSA values (<2.0ng/mL). \(^{18}\)F-fluciclovine, one of the initially available radiotracers in the U.S., images amino acid metabolism. The detection of prostate bed recurrences and nodal metastases in patients with biochemically recurrent disease, with PSA values still below 1.0, varies between 21% and 72%. The detection rate appears dependent upon both PSA kinetics and histologic grade. The smallest short-axis diameter of nodes exhibiting uptake is reported at between 4 and 9mm, superior to CT. The detection of osseous metastases by \(^{18}\)F-fluciclovine appears comparable to standard bone scintigraphy although studies are limited.

Since the initial publication of this guideline, the FDA has approved two new PET agents for the management of advanced prostate cancer, \(^{68}\)Ga-PSMA-11 and \(^{18}\)F-DCFPyL. PSMA is a transmembrane protein highly overexpressed in over 90% of prostate cancers. \(^{68}\)Ga-PSMA-11 is a radiolabeled small molecule that binds to the PSMA receptor. It has high specificity and sensitivity and outperforms standard CT and MRI in detection of nodal and osseous metastases. In a recent prospective study of men who had undergone prostatectomy and had a rising PSA still under 2.0ng/mL, PSMA PET detected occult metastases significantly more frequently than fluciclovine-PET with an odds ratio over 4.57 \(^{18}\)F-DCFPyL, another small molecule that binds to the extracellular domain of PSMA with high affinity, was
shown to have a correct localization rate of 84.8% to 87.0% in a study of 208 men with rising PSA and negative conventional imaging following curative intent surgery or radiotherapy. Both $^{68}$Ga-PSMA-11 and $^{18}$F-DCFPyL are indicated for patients with suspected prostate cancer metastasis considering surgery or radiation therapy and also indicated for patients with suspected prostate cancer recurrence based on elevated serum PSA levels. The role of PSMA PET in assessing indications and response for metastatic patients is still under investigation. Additional PSMA agents are currently under investigation. PET agents such as $^{11}$C-choline have FDA approval but are no longer in routine use for prostate cancer due to lower sensitivity and specificity for metastatic disease compared to other agents. Further, the short half-life of $^{11}$C-choline requires that it be manufactured on site, so it is impractical for most centers.

While advanced imaging tests may enhance detection of metastatic lesions, the impact on patients and OS has yet to be fully demonstrated. It is still unclear what may be gained by the early detection of recurrent disease. In instances of planned salvage radiation therapy or salvage lymphadenectomy, the treatment templates may be adjusted as a result of novel imaging findings. In addition, oligometastatic disease may be identified, and such patients may be offered enrollment in clinical trials. While such approaches may be intuitively appealing, to date there is a limited amount of evidence suggesting benefit in terms of a delay in disease progression (ORIOLE) or improvement in OS (SABR-COMET). There is still limited evidence that metastasis-directed therapy (MDT) confers a survival benefit.

**Treatment**

7. **For patients with a rising PSA after failure of local therapy and no demonstrated metastatic disease by imaging, clinicians should offer observation or clinical trial enrollment. (Clinical Principle)**

Currently there are no systemic treatments with proven efficacy in men without metastatic disease who have received maximal local therapy. The overall course of a rising PSA after failure of local therapy is highly variable, with earlier recurrences indicative of more aggressive disease. In a study of men with biochemical recurrence after salvage radiotherapy, over half of the PSA failures occurred within 18 months of radiation, and these men were at a significantly higher risk of distant metastasis and death compared to men with later PSA recurrences.

Two large observational studies have assessed the question of salvage systemic therapy, and neither found an advantage for earlier treatment in terms of metastasis or survival. One study utilized the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database and the other assessed patients cared for in three managed care organizations. In both studies, patients treated with immediate ADT upon biochemical recurrence had a similar mortality risk as those whose ADT was deferred. Notably, a subgroup analysis of men in the managed care study found an apparent survival benefit of early salvage ADT in those with a PSADT of less than nine months. There has been one prospective RCT seeking to compare immediate with delayed ADT (TOAD). While this study did not reach its accrual goals, enrolling 261 of a planned 750 patients, there was a borderline significant improvement in OS with early ADT (HR=0.55; 95% CI: 0.30 to 1.00; p=0.050). Given the small sample size and inclusion of some patients who did not receive prior local therapy, these data are insufficient to support a recommendation of early systemic therapy after biochemical recurrence for most men.

Any potential benefit of early initiation of systemic therapy must also be weighed against the impact of treatment of adverse events and QOL. In the TOAD trial, men in the early ADT arm had higher rates of hormone-treatment-related symptoms and inferior QOL related to sexual activity.

While observation or a clinical trial is preferred, it is recognized that ADT is sometimes given to men with rapid PSA rises in the absence of radiographic metastases in an attempt to delay the appearance of metastases. There is no evidence to determine the best time to start ADT in the absence of radiographic metastases.

8. **ADT should not be routinely initiated in this population (Expert Opinion). However, if ADT is initiated in the absence of metastatic disease, intermittent ADT may be offered in lieu of continuous ADT. (Conditional Recommendation; Evidence Level: Grade B)**

If men start ADT prior to demonstration of metastatic disease, it is often due to the perception of a higher risk
of progression to metastatic prostate cancer based on prognostic criteria such as a higher grade or stage, shorter time to biochemical recurrence, and shorter PSADT. Although not recommended, if ADT is initiated in the absence of visible metastases for men who have completed maximal local therapy, intermittent ADT may be offered instead of continuous ADT.

If ADT is initiated, RCTs have demonstrated the safety of an intermittent approach. An open-label trial by Crook et al. (n=1,386) compared intermittent versus continuous ADT in patients with a PSA rise to >3ng/mL more than 1 year following primary or salvage radiotherapy for localized prostate cancer. An important limitation of this study to note is the lack of any stratifying criteria or initial risk factors. Intermittent therapy consisted of an eight-month treatment cycle. At the end of the 8-month cycle, treatment was discontinued if there was no evidence of clinical disease progression, the PSA level was <4ng/mL, and did not increase more than 1ng/mL. It is further noted that the PSA threshold to reinitiate the next cycle of ADT was a level of 10ng/mL. At a median follow-up of 6.9 years, there was no difference in survival between intermittent versus continuous ADT (median 8.8 versus 9.1 years, (HR=1.02; 95% CI: 0.86 to 1.21), meeting the predefined non-inferiority threshold. There was also no difference in prostate cancer-specific survival (HR=1.18; 95% CI: 0.90 to 1.55). Intermittent therapy was associated with better scores for hot flashes (p<0.001), desire for sexual activity (p<0.001), and urinary symptoms (p=0.006) compared with continuous therapy.

The open-label EC507 trial (n=109) compared intermittent versus continuous ADT in patients with a PSA increase to ≥1ng/mL following an initial decrease to <0.5ng/mL within 3 months of radical prostatectomy. All patients underwent induction with leuprolein acetate, and patients who achieved a PSA level <0.5ng/mL during induction were randomized to intermittent versus continuous ADT. In the intermittent therapy arm, ADT was resumed if PSA levels increased to ≥3ng/mL. The primary outcome of the trial was testosterone recovery, which was achieved in 79.3% of patients in the first intermittent ADT cycle and 64.9% during the second intermittent ADT cycle. There was no difference between intermittent versus continuous ADT in time to castration resistance (mean 976 versus 986 days, p=0.85); OS and PFS were not reported.

The presence and extent of metastatic disease plays a central role in determining which and if any therapy is beneficial. Patients without metastatic disease have not been shown to benefit from aggressive systemic therapy. Further, clinicians should categorize patients as de novo metastatic disease or having progression in stage after prior failed treatment. Studies of systemic therapy have demonstrated that extent of metastatic disease influences response. For example, STAMPEDE demonstrated that only the subset of men with low-volume disease showed an improvement in survival with radiotherapy in combination with ADT. As a result, presence of metastatic disease, its burden, and precise locations should be assessed prior to treatment.

Patients diagnosed with aggressive cancer defined by D'Amico risk factors (cT3a or greater, Grade Group 4/5, or PSA>20ng/mL) should undergo routine bone scan and cross-sectional imaging (CT or MRI) or PET imaging at the time of diagnosis. PSMA PET availability is increasing in the U.S. and detects metastatic disease at low PSA values. As outlined above, the extent and location of metastasis should be documented. Imaging should be repeated for men who undergo treatment at the time of PSA failure. It is notable that the median PSA at which metastasis is detected after curative intent is highly variable in some studies with a median of 31ng/mL and a range of 0.2 to 798.5ng/mL. Factors associated with rapid progression to metastatic disease include short PSADT, a high pathologic or biopsy Gleason score after radical prostatectomy, and a short interval to biochemical failure. In addition, it is notable that men with de novo metastases appear to do worse than men who develop metastatic disease subsequent to radiation or surgery. It is unknown if this is due to a therapeutic effect, lead time bias, or ascertainment bias.

PET imaging detects metastatic disease at low PSA values and, therefore, has changed our ability to identify
low-volume metastatic disease. $^{18}$F-Fluciclovine is available and approved for patients for whom local therapy fails to control disease. Men with PSA over 1.0ng/mL were found to have avid lesions in 57% of cases.\textsuperscript{71} Both $^{68}$Ga-PSMA-11 and $^{18}$F-DCFPyL are indicated for patients with suspected prostate cancer metastasis considering local therapy and as well as for patients with suspected prostate cancer recurrence based on elevated serum PSA levels. Utilization of PSMA PET may lead to the diagnosis of metastatic disease not previously detected with conventional imaging. While this detection of metastases at lower PSA levels is helpful in guiding therapy, it is important to note that the clinical trials for treatment did not use PET imaging; therefore, it is unknown if volume of disease on PET imaging can accurately classify patients into high- and low-risk groups.

10. In newly diagnosed mHSPC patients, clinicians should assess the extent of metastatic disease (low- versus high-volume). High-volume is defined as greater than or equal to four bone metastases with at least one metastasis outside of the spine/pelvis and/or the presence of visceral metastases. (Moderate Recommendation: Evidence Level: Grade B)

Irrespective of presentation (e.g., de novo or progression following local curative-intent therapy), patients with metastatic disease should be evaluated with conventional imaging with consideration of chest CT imaging to assess the location and extent of metastatic disease. Although there is no compelling evidence supporting any particular prognostic model for metastatic prostate cancer, there is evidence from prospective randomized trials indicating the utility of defining the extent of disease to help select patients more likely to benefit from the addition of agents such as docetaxel to standard ADT.

In CHAARTED,\textsuperscript{72} patients were prospectively defined as having low- or high-volume disease, with high-volume disease defined as presence of visceral metastases and/or greater than or equal to four bone metastases with at least one outside of the vertebral column and pelvis. The study showed clinical benefit from chemohormonal therapy in prolonging OS, but only in high-volume disease patients (HR=0.63; 95% CI: 0.50 to 0.79; P<.001). No OS benefit observed in patients with low-volume disease (HR=1.04; 95% CI: 0.70 to 1.55; P=.86).

11. Clinicians should assess if a newly diagnosed mHSPC patient is experiencing symptoms from metastatic disease at the time of presentation to guide discussions of prognosis and further disease management. (Moderate Recommendation; Evidence Level: Grade B)

Symptoms in mHSPC have been shown to have prognostic value. In addition, understanding cancer related symptoms is key to optimizing pain and other symptom management in addition to anti-cancer therapy. In an analysis of patients in the SWOG 8894 trial, presence of bone pain (adjusted OR=2.61; 95% CI: 1.66 to 4.12) was among the factors associated with poorer 10-year survival.\textsuperscript{73}

12. Clinicians should obtain a baseline PSA and serial PSAs at three- to six-month intervals after initiation of ADT in mHSPC patients and consider periodic conventional imaging. (Clinical Principle)

The use of PSA as an instrument of evaluation in metastatic prostate cancers is common practice. In most reported studies, PSA is a measured variable and recorded at several time points at diagnosis and during treatment (baseline, induction [after a defined period of therapy], serial monitoring, and at progression). In many studies, PSA has demonstrated clear prognostic value and is used in many of the risk classification systems. For example, in the SWOG 8894 trial, a comparison of bilateral orchectomy with or without flutamide for treatment of metastatic prostate cancer, many clinical factors were analyzed in the assessment of risk including the finding that a higher PSA (adjusted OR=1.18 for log PSA; 95% CI: 1.03 to 1.34) was associated with poorer 10-year survival.\textsuperscript{73}

Studies using the SEER registry database have found higher PSA is associated with worse cancer-specific survival (PSA <60 versus ≥60: HR=0.624; 95% CI: 0.535 to 0.727).\textsuperscript{74} Additionally, for studies showing prognostic risk group stratification, PSA or PSA metrics are consistent variables in determination of group assignment.\textsuperscript{75-77}

PSA decline after initiation of ADT (nadir) has been shown to be prognostic based on several studies and is useful in patient counseling. It is also likely useful in risk stratification for clinical trials. There are several
prospective studies that have demonstrated the power of the PSA nadir in risk stratification. In an early analysis of SWOG 9346 looking at intermittent ADT in patients with metastatic prostate cancer, results demonstrated that PSA nadir at 7 months, \(<4\text{ng/mL}\) versus \(>4\text{ng/mL}\), risk stratified patients receiving ADT, showing median survivals of 69 months versus 16 months, \(p<0.0001\). This was followed by a later analysis of SWOG 9346 trial demonstrating that PSA nadir after six to seven months of ADT in newly diagnosed metastatic prostate cancer patients was prognostic for survival. An initial analysis demonstrated 3 prognostic groups could be identified based on PSA nadir; PSA \(>4\), PSA 0.2 to 4, and PSA \(<0.2\) with median survivals of 13 months, 44 months, and 75 months, respectively \((p<0.001)\). Obtaining PSA at three-to-six-month intervals allows for determination of the nadir and risk group stratification, and assists in patient counseling and setting expectations. With the changes in systemic therapy combinations, it is important to validate the prognostic value of nadir in more contemporary systemic settings. A recent analysis of the CHAARTED study showed PSA nadir at 7 months was a strong prognostic factor for OS when comparing nadirs \(<0.2\text{ng/mL}\) versus \(>4\text{ng/mL}\) (60.4 months versus 22.2 months, \(p<0.001\)). Similar analyses are being explored from RCTs previously evaluating abiraterone acetate as well as second-generation AR targeted therapies to demonstrate progression in the absence of PSA changes or in the absence of symptoms and should be considered as a method of evaluation of these patients. At the current time, recommendations are solely for conventional imaging, but as new tracers are introduced they may play a role in disease assessment.

13. In patients with mHSPC, clinicians should offer germline testing, and consider somatic testing and genetic counseling. (Clinical Principle)

There should be consideration of genetic testing for all metastatic hormone-sensitive patients, when possible, regardless of family or personal history of cancer. In a recent study evaluating 20 DNA-repair genes associated with autosomal dominant cancer-predisposition syndromes in a population of men with metastatic prostate cancer and unselected by family history, the prevalence of inherited (germline) DNA repair mutations was 11.8%. Findings of alterations in homologous recombination DNA repair (e.g., BRCA1/2, ATM, CHEK2, RAD51D, and PALB2) or tumor mutations resulting in MSI and deficient MMR may have implications in clinical trial eligibility or therapeutics selection (PARP, immunotherapy, or possibly early use of cytotoxic chemotherapy).

Germline testing should include, when possible, counseling by someone knowledgeable about the implications of testing. Counseling may include a discussion of possible test results; implications for patients; discussion of the Genetic Information Nondiscrimination Act (GINA); possible impact of test results on life, disability, and long-term care insurance;
and potential role of cascade testing of family members if a pathogenic or likely pathogenic mutation is identified. Post-test counseling with a genetic counselor is necessary for anyone who is found to have one of these mutations.

**Treatment**

14. **Clinicians should offer ADT with either LHRH agonists or antagonists or surgical castration in patients with mHSPC.** (*Strong Recommendation; Evidence Level: Grade B*)

The use of primary ADT for the management of mHSPC has been the SOC since its discovery by Huggins et al. in the 1940's. Castrate levels of testosterone (<50ng/dL) may be achieved with LHRH analogues, gonadotropin-releasing hormone (GnRH) antagonists, or orchiectomy. These treatments are considered equivalent in cancer control, although they have never been compared in large RCTs. GnRH antagonists and orchiectomy as monotherapy have a rapid onset of action and avoid the 'testosterone flare' seen with LHRH analogues alone making them useful in situations needing rapid hormone ablation such as impending spinal cord compression.

At the time of initial publication of this guideline, the methods for achieving castrate levels of testosterone were either surgical or injectable. On December 18, 2020, the FDA approved relugolix as the first oral GnRH receptor antagonist for adult patients with advanced prostate cancer. Approval was based on the phase III HERO study that showed favorable testosterone suppression and adverse effects of oral relugolix (120mg/day) compared to leuprolide.

15. **In patients with mHSPC, clinicians should offer ADT in combination with either androgen pathway directed therapy (abiraterone acetate plus prednisone, apalutamide, enzalutamide) or chemotherapy (docetaxel).** (*Strong Recommendation; Evidence Level: Grade A*)

mHSPC remains an incurable manifestation of the disease. While ADT, with or without non-steroidal antiandrogens, has been the backbone of mHSPC treatment for many decades, ADT alone is no longer considered sufficient treatment for mHSPC. In just the past five years, multiple studies have shown that additional therapy significantly extends OS and PFS in mHSPC patients.

**Docetaxel**

Docetaxel is a potent inhibitor of microtubule assembly and disassembly. Since 2015, 2 clinical trials demonstrated the benefits of adding docetaxel chemotherapy to ADT for mHSPC patients. In the phase III CHAARTED study, 790 patients with mHSPC were equally randomly assigned to receive either ADT in combination with docetaxel (75mg/m²) for up to 6 cycles or ADT alone. In an updated reporting on the trials, at a median follow-up of 53.7 months, the median OS was 57.6 months for the chemohormonal therapy arm versus 47.2 months for ADT alone (HR=0.72; 95% CI: 0.59 to 0.89; P=0.0018). The median time to clinical progression was 33.0 months for the combination arm versus 19.8 months in the ADT alone arm (HR in the combination arm=0.62; 95% CI: 0.51 to 0.75; P<0.001).

Similarly, in the STAMPEDE trial, ADT plus docetaxel significantly improved median OS compared with ADT alone. The study randomly assigned 2,962 men 2:1:1:1 to receive SOC defined as hormone therapy for at least 2 years, SOC plus zoledronic acid, SOC plus docetaxel, or SOC with zoledronic acid and docetaxel. Docetaxel (75mg/m²) was given for six 3-week cycles with prednisolone (10mg) daily. Patients were followed up 6-weekly to 6 months, 12-weekly to 2 years, 6-monthly to 5 years, then annually. At a median follow-up of 43 months, median OS was 71 months for SOC compared to 81 months for SOC plus docetaxel (HR=0.78; 95% CI: 0.66 to 0.93; P=0.006). SOC plus docetaxel also improved median failure-free survival at 37 months compared 20 months with SOC alone. The durability of these results was supported in an update of this trial. At a median follow-up of 78.2 months, there were 494 deaths on SOC. There was good evidence of benefit in docetaxel over SOC on OS (HR=0.81; 95% CI: 0.69 to 0.95; P=0.009). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR=0.66; 95% CI: 0.57 to 0.76; P<0.001) and PFS (HR=0.69; 95% CI: 0.59 to 0.81; P<0.001).

Like many chemotherapy agents, docetaxel has a significant toxicity profile that needs consideration. In the STAMPEDE trial, the most frequently reported adverse events in the SOC plus docetaxel group included febrile neutropenia (15%), general disorder (including lethargy,
fever, asthenia—7%), and gastrointestinal disorder (including diarrhea, abdominal pain, constipation, vomiting—8%).

**ABIRATERONE ACETATE**

Abiraterone acetate is a non-steroidal irreversible inhibitor of CYP17A1, which catalyzes the conversion of C21 progestosterone precursors to C19 adrenal androgens, DHEA, and androstenedione. In essence, abiraterone acetate is similar to ADT, but it is more potent, inhibiting gonadal and extragonadal androgen synthesis.

In the double-blind, placebo-controlled, phase III LATITUDE trial, 1,199 patients were randomly assigned to receive either ADT plus abiraterone acetate (1,000mg given once daily as four 250mg tablets) plus prednisone (5mg daily) or ADT plus placebo. The primary endpoints were OS and radiographic PFS. After a median follow-up of 30.4 months at a planned interim analysis, the median OS was significantly longer in the abiraterone acetate group than in the placebo group (not reached versus 34.7 months) (HR=0.62; 95% CI: 0.51 to 0.76; P<0.001). The median length of radiographic PFS was 33.0 months in the abiraterone acetate group and 14.8 months in the placebo group (HR=0.62; 95% CI: 0.52 to 0.76; P<0.001). Updated results continue to confirm benefit in this trial. The final analysis of this trial, at a median follow-up of 51.8 months, OS was significantly longer in the abiraterone acetate plus prednisone group (median 53.3 months [95% CI: 48.2 to not reached]) compared to the placebo group (36.5 months [33.5 to 40.0]), with an HR of 0.66 (95% CI: 0.56 to 0.78; P<0.0001).

In the STAMPEDE trial, 1,917 patients were randomized in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1,000mg daily) and prednisolone (5mg daily). A total of 52% of patients had metastatic disease. The primary outcome was OS. The median follow-up was 40 months. There were 184 deaths in the abiraterone acetate group compared with 262 in the ADT group (HR=0.63; 95% CI: 0.52 to 0.76; P<0.001); the HR was 0.61 in those with metastatic disease.

Abiraterone acetate can elevate liver enzyme levels and should be avoided in patients where liver toxicity is a concern. As such, clinicians should monitor liver enzymes as well as potassium levels. Adverse events in the LATITUDE trial included mineralocorticoid-related hypertension (20%) and hypokalemia (10%). Further, the use of a steroid in combination with treatments for metastatic disease may require additional considerations for patients with comorbid conditions, such as diabetes or significant osteoporosis.

**APALUTAMIDE**

Apalutamide is a novel androgen receptor signaling inhibitor (ARSI). This oral agent acts as an AR inhibitor that binds directly to the ligand-binding domain of the AR. Apalutamide inhibits AR nuclear translocation, inhibits DNA binding, and impedes AR-mediated transcription. In the double-blind, phase III TITAN study, 525 patients were assigned to receive apalutamide (240mg daily) with ADT compared to 527 patients receiving placebo plus ADT. Primary endpoints included radiographic PFS and OS. At a median of 22.7 months follow-up, the percentage of patients with radiographic PFS at 24 months was 68.2% in the apalutamide group compared to 47.5% in the placebo group (HR=0.48; 95% CI: 0.39 to 0.60; P<0.001). OS at 24 months was greater with apalutamide compared to placebo (82.4% versus 73.5%; HR=0.67; 95% CI: 0.51 to 0.89; P=0.005). At the time of final analysis (44.0 months median follow-up), a total of 405 deaths had occurred (170 in the apalutamide arm, 235 in the placebo arm). An improvement in median OS was observed: not reached in the apalutamide group versus 52.2 months in the placebo group (HR=0.65; 95% CI: 0.53 to 0.79; P<0.0001), with a 35% reduction in risk of death. Rash of any grade was more common among patients who received apalutamide compared to those who received placebo (27.1% versus 8.5%).

**ENZALUTAMIDE**

Enzalutamide is a novel ARSI. It is a competitive inhibitor of androgen binding and also inhibits nuclear translocation of the AR, DNA-binding and coactivator recruitment. In the open-label, randomized, phase III ENZAMET trial, 1,125 men were randomized to receive testosterone suppression plus either open-label enzalutamide (160mg daily) or a standard non-steroidal antiandrogen therapy (bicalutamide, nilutamide, or flutamide—standard care). The primary end point was OS. With a median follow-up of 34 months, there were 102 deaths in the enzalutamide group compared to 143 deaths in the standard care group (HR=0.67; 95% CI: 0.52 to 0.86; P=0.002). Kaplan-Meier estimates of OS at 3 years were 80% in the enzalutamide group and 72% in the standard care group.
Discontinuation of treatment due to adverse events was more frequent in the enzalutamide group (33 events versus 14 events, respectively). Fatigue was more common in the enzalutamide group, and seizures occurred in 7 patients in the enzalutamide group (1%) compared to 0 patients in the standard care group. In this trial, approximately 16% of patients also received docetaxel and this study did not impact the observed benefit of enzalutamide. This trial did not address the role of early intensification by adding docetaxel to enzalutamide.

In the double-blind, phase III ARCHES trial, Armstrong et al. randomly assigned 1,150 men with mHSPC in a 1:1 ratio to receive either enzalutamide (160mg per day) or placebo. All patients also received ADT. The primary endpoint was radiographic PFS. As of October 2018, the risk of radiographic PFS or death was significantly reduced with enzalutamid plus ADT versus placebo plus ADT (median not reached versus 19.0 months; HR=0.39; 95% CI: 0.30 to 0.50; <0.001). Similar improvements were also seen in risk of PSA progression, initiation of new antineoplastic therapy, first symptomatic skeletal event, castration-resistance, and reduced risk of pain progression. In an update on this trial, the final prespecified analysis of OS, which was a key secondary end point, and an update on radiographic PFS was reported. Following unblinding, 180 (31.3%) progression-free patients randomly assigned to placebo plus ADT crossed over to open-label enzalutamide plus ADT. At a median follow-up of 44.6 months, 154 of 574 patients randomly assigned to enzalutamide plus ADT and 202 of 576 patients randomly assigned to placebo plus ADT had died. Enzalutamide plus ADT reduced risk of death by 34% versus placebo plus ADT (median not reached in either group; HR=0.66; 95% CI: 0.53 to 0.81; <0.001).95

Enzalutamide, apalutamide, and darolutamide do present a small risk of seizures, so patients with a seizure disorder should instead choose a drug like abiraterone acetate plus prednisone or docetaxel.

**THERAPEUTIC DECISION-MAKING IN MHSPC**

Unfortunately, no comparative data on efficacy exist between the previously discussed options. The clinician should consider factors like age and comorbidities when choosing chemotherapy, where toxicity might be more difficult for older patients than fit younger patients. Duration of treatment may also influence choice. Some patients might prefer a limited 18-week course of docetaxel to daily oral therapy for years. Further, in select patients with metastatic presentations, particularly de novo metastatic patients, triplet therapy is recommended (see following statement).

In terms of intermittent ADT, SWOG 9346 evaluated intermittent ADT compared with continuous ADT and did not demonstrate non-inferiority in mHSPC. In fact, there was a non-significant benefit in OS with continuous ADT. Given all of the recent data suggesting that additional therapy (chemotherapy or androgen receptor-targeted therapy [ART]) added to continuous ADT significantly improves OS, the Panel generally advises against intermittent ADT in otherwise healthy patients with mHSPC.

16. In selected patients with de novo mHSPC, clinicians should offer ADT in combination with docetaxel and either abiraterone acetate plus prednisone or darolutamide. (Strong Recommendation; Evidence Level: [Abiraterone] Grade A/[Darolutamide] Grade B)

The optimal patient for consideration of “dual intensification” or “triplet therapy” are best represented by the patients enrolled in the following two completed trials who are patients with de novo disease and are free of major comorbidities.

Two recent phase III randomized trials have demonstrated improvement in OS of patients receiving either abiraterone acetate (with prednisone) or darolutamide in addition to ADT and docetaxel in selected patients with de novo metastatic prostate cancer.

The PEACE-1 trial enrolled 1,173 patients with de novo metastatic prostate cancer who were randomized to receive ADT plus docetaxel (considered the SOC) plus radiotherapy, SOC plus abiraterone/prednisone or SOC plus abiraterone/prednisone and radiotherapy. In the initial analysis of the study, patients treated with SOC plus abiraterone/prednisone had an improvement in both OS (HR=0.82; 95.1% CI: 0.69 to 0.98; p<0.030) and radiographic PFS (HR=0.54; 99.9% CI: 0.41 to 0.71; p=0.0001) with some increase in toxicity in the abiraterone group, primarily being more hypertension. Data from the radiotherapy arms are anticipated in the near future.97
The ARASENS phase III study enrolled 1,306 patients with mHSPC (86.1% of enrolled patients had de novo metastatic disease) and randomized them to receive either darolutamide or placebo in combination with ADT and docetaxel. The trial demonstrated that the combination of darolutamide plus ADT/docetaxel resulted in improved OS, with the risk of death reduced by 32.5% (HR=0.68; 95% CI: 0.57 to 0.80; P<0.001). The frequency of grade 3/4 events was similar between the treatment arms.98

As the majority of patients treated in both PEACE-1 and ARASENS had de novo metastatic disease, the role of “dual intensification” or “triplet therapy” in patients with mHSPC with progression following curative-intent local therapy remains undefined.

17. In selected mHSPC patients with low-volume metastatic disease, clinicians may offer primary radiotherapy to the prostate in combination with ADT. (Conditional Recommendation; Evidence Level: Grade C)

Two recent phase III randomized trials examining ADT and prostate radiotherapy versus ADT alone in men with metastatic prostate cancer demonstrated no difference in OS. However, the subgroup analysis for the low-volume group in STAMPEDE Arm H revealed a survival benefit in patients with low-volume metastatic cancer.69 Given this was a secondary analysis, and that few of the patients had received optimized systemic therapy, the Panel provides a conditional recommendation for ADT plus radiation as an option for patients with minimal metastatic disease willing to undergo the risks associated with local therapy.

The HORRAD trial reported on 432 patients randomized either to ADT alone or ADT with EBRT to the prostate.99 Median PSA was 142ng/mL, and 67% of patients had more than 5 osseous metastases by conventional imaging. OS was not different (HR=0.9; 95% CI: 0.7 to 1.14; p=0.4), but median time to PSA progression was improved in the EBRT arm (HR=0.78; 95% CI: 0.63 to 0.97; p=0.02). A hypothesis was generated that survival might be improved in a subgroup of patients with low metastatic burden (HR=0.68; 95% CI: 0.42 to 1.10). In the STAMPEDE trial, 2,061 men with metastatic HSPC were randomized to ADT alone versus ADT plus prostate radiation given at moderate doses and with unconventional fractionation (36Gy in 6 fractions over 6 weeks, or 55Gy in 20 daily fractions).69 Radiotherapy improved failure-free survival (HR=0.76; 95% CI: 0.68 to 0.84; p<0.0001), but not OS (HR=0.92; 95% CI: 0.80 to 1.06; p=0.266) similar to HORRAD. An additional pre-specified analysis utilizing the CHAARTED definition of low-volume cancer encompassing 40% of the population was performed. Low-volume metastatic disease demonstrated a benefit to ADT plus radiation (HR=0.68; 95% CI: 0.52 to 0.90; p=0.007) with 3-year survival 73% with ADT alone versus 81% with ADT and radiotherapy. Toxicity is important to minimize in patients who will not be cured of their metastatic disease. There was no significant difference in grade ≥3 toxicity with the addition of radiotherapy (HR=1.01; 95% CI: 0.87 to 1.16; p=.94).

Physicians have suggested these results point to the benefits of local therapy raising the question whether radical prostatectomy might have the same results. These trials are ongoing, and at present the use of surgery should be considered investigational and only conducted within the context of a trial. In the STAMPEDE trial,69 no patients had concurrent abiraterone acetate, and only 18% had early docetaxel so no clear recommendation can be made about other drug combinations combined with prostate radiation in the metastatic setting.

18. Clinicians should not offer first generation antiandrogens (bicalutamide, flutamide, nilutamide) in combination with LHRH agonists in patients with mHSPC, except to block testosterone flare. (Strong Recommendation; Evidence Level: Grade A)

With compelling level A evidence supporting the use of docetaxel, abiraterone acetate plus prednisone, apalutamide, or enzalutamide in combination with ADT in men with newly diagnosed mHSPC, the Panel believes that long-term use of first generation antiandrogens bicalutamide, flutamide, nilutamide in lieu of the above noted agents cannot be supported.

In the first week after LHRH agonists are administered, there is typically a surge in luteinizing hormone resulting in an increase in circulating testosterone. This may cause clinical “flares,” which may be associated with worsening of disease symptoms (e.g., bone pain, urinary tract obstruction) in approximately 10% of patients. This surge can be “blocked” by short term (e.g., 4 weeks or less) of a first-generation antiandrogen, although there is limited evidence of significant clinical utility.100
19. Clinicians should not offer oral androgen pathway directed therapy (e.g., abiraterone acetate plus prednisone, apalutamide, bicalutamide, darolutamide, enzalutamide, flutamide, nilutamide) without ADT for patients with mHSPC. (Expert Opinion)

Non-steroidal antiandrogen therapy without ADT in advanced prostate cancer is not recommended. Evidence based on 11 studies encompassing 3,060 patients suggests that use of non-steroidal antiandrogens without ADT compared with medical or surgical castration monotherapy for advanced prostate cancer is less effective in terms of OS, clinical progression, treatment failure, and treatment discontinuation due to adverse events.101

Bicalutamide, flutamide and nilutamide are first generation antiandrogens extensively studied in combination with either bilateral orchiectomy or LHRH agonists in mHSPC.102-106 There is insufficient evidence to support the use of first generation antiandrogens as monotherapy.102,107-109

Abiraterone acetate is an inhibitor of CYP17, and apalutamide, darolutamide, and enzalutamide are second generation antiandrogens. None of these agents have been studied without ADT for mHSPC, while compelling evidence of survival has been demonstrated with testosterone suppression in combination with either abiraterone acetate plus prednisone, enzalutamide, or apalutamide.24,69,91,94,110,111 For now, however, these next generation antiandrogens should not be considered without ADT in mHSPC.

NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Prognosis

20. In nmCRPC patients, clinicians should obtain serial PSA measurements at three- to six-month intervals, and calculate a PSADT starting at the time of development of castration-resistance. (Clinical Principle)

Monitoring of men with nmCRPC should include serial measurements of PSA, whether patients are receiving ADT alone or ADT with an additional AR directed therapy (apalutamide, darolutamide, enzalutamide). This allows clinicians to monitor disease status and should be performed every three- to six-months. PSADT should be calculated for men with a rising PSA in the setting of ongoing ADT (castration-resistance) as PSADT is useful in determining which men are at highest risk of developing metastatic lesions or dying from prostate cancer.112 PSADT <10 months was used to identify the highest risk population for inclusion in the three trials that led to approval of the AR antagonists for men with nmCRPC and is recommended to consider when adding one of the medications to ADT in men with nmCRPC.9-11 However, FDA approval of these agents does not specify a doubling time.

21. Clinicians should assess nmCRPC patients for development of metastatic disease using conventional or PSMA PET imaging at intervals of 6 to 12 months. (Expert Opinion)

In addition to monitoring PSA, routine use of conventional or PSMA PET imaging should be integrated into monitoring the disease status of men with nmCRPC. The suggested interval of imaging is 6 to 12 months, with the exact interval determined by the PSADT calculation, the development of symptoms, and patient/physician preference. A PSADT of ≤10 months is associated with a high risk of developing metastatic disease or dying from prostate cancer.112 Continued monitoring with routine imaging is recommended for patients on ADT alone and patients on ADT plus an AR antagonist (apalutamide, darolutamide, enzalutamide). In patients with mCRPC treated with enzalutamide prior to chemotherapy in the PREVAIL trial, radiographic progression occurred in 24.5% of patients without PSA progression, suggesting that routine imaging can identify a significant portion of patients with radiographic progression who would otherwise not be identified.113 We extrapolate this principle to the nmCRPC population, particularly for men on additional AR antagonist treatment.

Once a patient has started ART therapy for nmCRPC as noted below, the imaging intervals can be extended to annually in the absence of other indicators of progression.
Treatment

22. Clinicians should offer apalutamide, darolutamide, or enzalutamide with continued ADT to nmCRPC patients at high risk for developing metastatic disease (PSADT ≤10 months). (Strong Recommendation; Evidence Level Grade A)

In the past clinicians used bicalutamide in the nmCRPC patient population as a method to reduce PSA in the absence of trials demonstrating a clinical benefit. In 2018, apalutamide became the first FDA-approved treatment for patients with non-metastatic disease; shortly thereafter, enzalutamide and darolutamide were also approved in this patient population. There are now three FDA approved agents that demonstrate superiority in terms of prolonging MFS by nearly two years. Bicalutamide is no longer a viable strategy for treatment of this patient population. It should also be noted that there are no head-to-head clinical trials demonstrating superiority of any one of these agents (apalutamide, darolutamide, enzalutamide) over the other two.

APALUTAMIDE

In the double-blind, placebo-controlled, phase III SPARTAN trial, Smith et al. randomly assigned 1,207 men in a 2:1 ratio to receive apalutamide (240mg per day) or placebo. All patients had a diagnosis of nmCRPC with a PSADT ≤10 months and continued on ADT. At the time of planned primary analysis, median MFS was 40.5 months in the apalutamide group compared to 16.2 months in the placebo group (HR=0.29; 95% CI: 0.24 to 0.35; P<0.001), representing a 72% reduction in the risk of distant metastasis or death. Median OS was not reached in the apalutamide group compared to 39.0 months in the placebo group (HR=0.70; 95% CI: 0.47 to 1.04; p=0.07). Secondary endpoints including time to symptomatic progression (HR=0.45; 95% CI: 0.32 to 0.63; P<0.001) and time to metastasis (HR=0.27; 95% CI: 0.22 to 0.34; p<0.001) were significantly longer in the apalutamide arm compared to placebo. Median PFS was 40.5 months in the apalutamide group versus 14.7 months in the placebo group (HR=0.29; 95% CI: 0.24 to 0.36; P<0.001). Overall, 10.6% of patients receiving apalutamide discontinued treatment due to adverse events compared to 7.0% of patients receiving placebo. The adverse events that occurred in ≥15% of patients in either group (apalutamide versus placebo) included fatigue, hypertension, rash, diarrhea, nausea, weight loss, arthralgia, and falls.

DAROLUTAMIDE

ARAMIS is a randomized, double-blind, placebo-controlled, phase III study assessing the safety and efficacy of darolutamide in men with nmCRPC. All patients had nmCRPC with a PSADT ≤10 months and PSA ≥2ng/mL (median 9.0 and 9.7ng/mL in the darolutamide versus placebo arms, respectively). The study enrolled 1,509 patients who were randomized in a 2:1 fashion to ADT with darolutamide or ADT with placebo, with a primary endpoint of MFS survival. The median MFS was 22 months longer with darolutamide compared to placebo (40.4 months with darolutamide versus 18.4 months with placebo, HR=0.41; 95% CI: 0.34 to 0.50; P<0.001). Median OS was not reached in either group, but there was a lower risk of death with darolutamide than placebo (HR=0.71; 95% CI: 0.50 to 0.99; P=0.045). The median time to PSA progression was 33.2 months versus 7.3 months in the darolutamide versus placebo groups, respectively (HR=0.13; 95% CI: 0.11 to 0.16; P<0.001). Treatment discontinuation due to adverse events occurred in 8.9% of patients receiving darolutamide compared to 8.7% receiving placebo.

ENZALUTAMIDE

PROSPER is a randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and tolerability of enzalutamide in nmCRPC patients. All patients had nmCRPC with a PSADT ≤10 months. The 1,401 patients were randomized (2:1) to enzalutamide 160mg per day or placebo. Both arms continued ADT. During the first interim analysis of OS, 103 patients (11%) in the enzalutamide group and 62 (13%) in the placebo group had died. Median OS was not reached in either group. As of June 2017, a total of 219 patients (23%) in the enzalutamide group had metastases or had died, as compared to 228 (49%) in the placebo group. Median MFS was approximately 22 months longer in the enzalutamide arm at 36.6 months compared with 14.7 months in the placebo group (HR=0.29; 95% CI: 0.24 to 0.35; P<0.001). Additionally, median time to PSA progression was approximately 33 months longer in patients receiving enzalutamide compared to those receiving placebo (37.2 months in the enzalutamide group compared to 3.9 months in the placebo group; HR=0.07; P<0.001). Following completion of the systematic review for this guideline, additional data were released on OS as...
of October 2019. In the enzalutamide group, the median OS was 67.0 months (95% CI: 64.0 to not reached) and 56.3 months (95% CI: 54.4 to 63.0) in the placebo group. Treatment with enzalutamide plus ADT was associated with a 27% lower risk of death versus placebo plus ADT (HR=0.73; 95% CI: 0.61 to 0.89; P=0.001).114 Adverse events as the primary reason for treatment discontinuation occurred in 87 patients (9%) receiving enzalutamide compared to 28 (6%) receiving placebo. Deaths due to adverse events on trial irrespective of attribution occurred in 32 patients (3%) receiving enzalutamide and 3 patients (1%) receiving placebo. Adverse events noted to occur more frequently with enzalutamide included convulsion, hypertension, neutropenia, memory impairment disorders, and major cardiovascular events.

Data from the STRIVE and TERRAIN trials115,116 suggest that bicalutamide is not a reasonable option for treatment of men with nmCRPC. In STRIVE, Penson et al. randomized (1:1) a mixed population of men diagnosed with non-metastatic (n=139) or metastatic (n=257) CRPC to receive enzalutamide 160mg per day or bicalutamide 50mg per day. Both arms remained on ADT. The treatment effect of enzalutamide on PFS was consistently favorable across all patient populations, and median PFS was not reached with enzalutamide in the non-metastatic population compared with 8.6 months with bicalutamide (HR=0.24; 95% CI: 0.14 to 0.42; p<0.001). PSA decline, defined as ≥50% and ≥90% decline from baseline, favored enzalutamide (enzalutamide: 91% versus bicalutamide: 42% and enzalutamide: 76% versus bicalutamide: 12%, respectively). Analysis of other secondary endpoints, such as decreased risk of radiographic progression or death, favored enzalutamide with a 76% risk reduction (HR=0.24; 95% CI: 0.10 to 0.56). In TERRAIN, men with mCRPC were randomized to treatment with ADT plus enzalutamide 160mg per day or bicalutamide 50mg per day, and were followed to assess the primary endpoint of PFS. Median PFS was significantly prolonged in men treated with enzalutamide when compared with bicalutamide (15.7 months versus 5.8 months for enzalutamide versus bicalutamide, respectively, HR 0.44, 95% CI: 0.34 to 0.57; p<0.0001).118

The Panel does not recommend the use of abiraterone acetate plus prednisone for men with nmCRPC because of other options and lack of an FDA-approved indication for this clinical space. However, in a single arm study of 131 men with nmCRPC at high risk of developing metastatic disease as identified by a PSADT of ≤10 months, patients treated with abiraterone acetate plus prednisone had a PSA significantly reduced by ≥ 50% in 86.9% of cases (p<0.0001).117 Additionally, median time to PSA progression was 28.7 months (95% CI: 21.2 to 38.2). The data are not considered sufficient to confirm clinical benefit in the nmCRPC population, particularly in the setting of three FDA approved alternative treatment options.

23. Clinicians may recommend observation with continued ADT to nmCRPC patients, particularly those at lower risk (PSADT >10 months) for developing metastatic disease. (Clinical Principle)

It is the Panel’s judgment that observation with continued ADT is recommended for patients with a PSADT >10 months. These patients have a lower risk of developing metastatic disease than patients with a PSADT ≤10 months.118 This statement is based on clinical principle rather than evidence as patients with a PSADT >10 months were not included in the clinical trials that led to the approval of apalutamide, darolutamide, or enzalutamide for nmCRPC; and the precise benefit/risk ratio for a given patient should be determined by the treating clinician.

24. Clinicians should not offer systemic chemotherapy or immunotherapy to nmCRPC patients outside the context of a clinical trial. (Clinical Principle)

The Panel strongly recommends against the use of chemotherapy, immunotherapy, or other agents not FDA approved for use in the nmCRPC setting. There is a lack of evidence suggesting benefit, and these agents, like any medication, have associated toxicity. The combination of no known benefit with known and potentially serious harms supports the decision to recommend against use of these agents in men with nmCRPC.
25. In mCRPC patients, clinicians should obtain baseline labs (e.g., PSA, testosterone, LDH, Hgb, alkaline phosphatase level) and review location of metastatic disease (lymph node, bone, visceral), disease-related symptoms, and performance status to inform discussions of prognosis and treatment decision-making. (Clinical Principle)

There are established laboratory and imaging characteristics known to be associated with prognosis among men with mCRPC. As such, it is recommended that a baseline laboratory and imaging assessment be performed to inform discussions around prognosis and clinical decision-making. Known laboratory risk-factors associated with increasing risk of mortality include elevated LDH, testosterone <20 to 50ng/dL, higher PSA, and shorter PSADT. There are established imaging findings also known to be associated with increasing risk of mortality. Increasing burden of metastatic disease in the form of the number of metastatic sites is associated with increasing risk of overall mortality. Additionally, there are known relationships between location of metastases and risk of mortality. Specifically, visceral metastases are known to portend the highest risk of mortality (HR=1.76; 95% CI: 1.34 to 2.32 versus lymph node) followed by bone metastases (HR=1.52; 95% CI: 1.20 to 1.93 versus lymph node).

In addition to laboratory and imaging parameters, performance status and the extent of disease-related symptoms are strongly associated with mortality. Numerous studies have characterized the inverse relationship between performance status and risk of mortality. Independently, prostate cancer-related pain is known to be strongly associated with the risk of mortality. Men with mCRPC represent a heterogeneous group with a wide distribution of disease-related symptoms. Given the known relationships between disease-related symptoms and prognosis, it is incumbent upon the treating clinician to perform a thorough symptom inventory at the time of assessment to ensure adequate symptom management and to incorporate the individual patient’s symptom burden into discussions around prognosis and treatment selection.

26. In mCRPC patients without PSA progression or new symptoms, clinicians should perform imaging at least annually. (Expert Opinion)

Response to treatment and/or disease progression among men with mCRPC may be evaluated through PSA testing, imaging, or change in disease-related symptoms. It is recommended that men with mCRPC undergo imaging at least annually, owing to the fact that in patients with mCRPC treated with enzalutamide prior to chemotherapy in the PREVAIL trial, radiographic progression occurred in 24.5% of patients without PSA progression. This suggests that routine imaging can identify a significant portion of patients with radiographic progression who would otherwise not be identified. The precise timing of imaging among men with mCRPC should be determined by multiple factors including biochemical response to treatment, change in disease-related symptoms, and patient preference. Furthermore, clinicians should consider known differences in biochemical response to treatment among different therapies for mCRPC when determining the interval between imaging studies.

27. In mCRPC patients with disease progression (PSA or radiographic progression or new disease-related symptoms) having previously received docetaxel and androgen pathway inhibitor, who are considering 177Lu-PSMA-617, clinicians should order PSMA PET imaging. (Expert Opinion)

The phase III VISION study enrolled 831 men with mCRPC previously treated with at least 1 androgen pathway inhibitor and 1 or 2 prior taxane regimens who had PSMA-positive 68Ga-PSMA-11 PET/CT’s. Patients were randomized 2:1 to receive either 177Lu-PSMA-617 every 6 weeks for 4 to 6 cycles plus protocol-permitted SOC versus SOC alone. At a median follow-up of approximately 21 months, 177Lu-PSMA-617 plus SOC improved both PFS and OS survival compared to SOC alone (median: 8.7 versus 3.4 months; HR=0.40; 99.2% CI: 0.29 to 0.57; P<0.001 and median: 15.3 versus 11.3 months; HR for death=0.62; 95% CI: 0.52 to 0.74; P<0.001, respectively). The incidence of grade 3 or higher adverse events was 52.7% versus 38% for 177Lu-PSMA-617 versus SOC, respectively; however, QOL was no different between the treatment arms.
28. In patients with mCRPC, clinicians should offer germline (if not already performed) and somatic genetic testing to identify DNA repair deficiency, MSI status, tumor mutational burden, and other potential mutations that may inform prognosis and familial cancer risk as well as direct potential targeted therapies. *(Clinical Principle)*

Germline mutations in genes involved in DNA damage repair (DDR) have been identified in over 11.8% of men with metastatic prostate cancer, with the most commonly identified gene mutations being *BRCA2*, *CHEK2*, *ATM*, and *BRCA1*. Germline mutations have been found to portend poor prognosis among men with metastatic prostate cancer. Specifically, cancer-specific survival among men found to be harboring a *BRCA2* mutation was found to be half of that among men without a defect in DDR (17.4 versus 33.2 months, *p*=0.027). Mutations in tumor suppressor genes have also been found to be associated with adverse outcomes among men with prostate cancer. Specifically, the presence of one or more mutations in tumor suppressor genes was found to be associated with increasing risk of death among men with metastatic disease.

Clinicians should offer germline and somatic testing to inform discussions around prognosis; however, germline testing may also be used to counsel patients regarding their family risk of associated malignancies. Finally, the landscape of evidence detailing the interactions between mutations and treatment individualization continues to evolve, and the use of genetic testing may ultimately enable the treating clinician to offer a personalized approach to prostate cancer treatment.

**Treatment**

29. In newly diagnosed mCRPC patients, who have not received prior androgen receptor pathway inhibitors, clinicians should offer continued ADT with abiraterone acetate plus prednisone, docetaxel, or enzalutamide. *(Strong Recommendation; Evidence Level: Grade A [abiraterone acetate plus prednisone and enzalutamide]/Grade B [docetaxel])*

Abiraterone acetate plus prednisone, enzalutamide, and docetaxel chemotherapy all have an FDA indication for use in men with mCRPC. For each agent, there is a randomized clinical trial that shows a survival benefit for men with mCRPC.

**ABIRATENERONE ACETATE**

In the placebo-controlled, double-blind, phase III COU-AA-302 study, Ryan et al. randomized 1,088 men with mCRPC who had not received prior chemotherapy to receive either abiraterone acetate 1,000mg daily plus prednisone 5mg twice a day or placebo plus prednisone 5mg twice daily. The primary outcomes of the study were radiographic-PFS and OS. Participants randomized to receive abiraterone acetate plus prednisone had statistically significant improvement in radiographic PFS (HR=0.53; *p*<0.001), as previously reported during interim analyses. The final analysis of OS showed a statistically significant increase in patients treated with abiraterone acetate plus prednisone (HR=0.81; 95% CI: 0.70 to 0.93; *P*=0.0033). The most common grades 3 to 4 adverse events were cardiac disorders (8% in the abiraterone acetate group versus 4% in the placebo group), increased alanine aminotransferase (6% versus <1%), and hypertension (5% versus 3%).

In the COU-AA-301 trial, de Bono et al. randomly assigned 1,195 patients who had previously received docetaxel in a 2:1 ratio to receive 5mg of prednisone twice daily with either 1,000mg abiraterone acetate or placebo. The primary endpoint was OS. After a median follow-up of 12.8 months, OS was 14.8 months in the abiraterone acetate group compared to 10.9 months in the placebo group (HR=0.65; 95% CI: 0.54 to 0.77; *P*<0.001). All secondary endpoints, including time to PSA progression, PFS, and PSA response rate favored the abiraterone acetate group.

**ENZALUTAMIDE**

In the double-blind, phase III PREVAIL study, Beer et al. randomized 1,717 chemotherapy-naïve patients to receive either enzalutamide (at a dose of 160mg) or placebo once daily. Co-primary endpoints were radiographic PFS and OS. The results showed that enzalutamide significantly decreased the risk of radiographic progression (HR=0.19; 95% CI: 0.15 to 0.23; *P*<0.001) and death (29% reduction in the risk of death; HR=0.71; 95% CI: 0.60 to 0.84; *P*<0.001). Enzalutamide also showed a benefit with respect to all secondary endpoints, including the time until the initiation of chemotherapy (HR=0.35; 95% CI: 0.30 to 0.40; *P*<0.001) in a group of men with mCRPC and a median follow-up.
duration for survival of approximately 22 months. Adverse events that occurred in 20% or more of patients receiving enzalutamide at a rate that was at least 2 percentage points higher than that in the placebo group were fatigue, back pain, constipation, and arthralgia.

In the phase III, double-blind AFFIRM study, Scher et al. stratified 1,199 men with CRPC after chemotherapy in a 2:1 ratio to receive enzalutamide (160mg per day) or placebo.\textsuperscript{17} The primary endpoint was OS. At the time of planned interim analysis, the median OS was 18.4 months in the enzalutamide group versus 13.6 months in the placebo group (HR for death in the enzalutamide group=0.63; 95% CI: 0.53 to 0.75; P<0.001). Enzalutamide was superior over placebo with respect to all secondary endpoints, including PSA reduction by 50% or more, soft-tissue response rate, QOL response rate, time to PSA progression, radiographic PFS, and the time to first SRE.

**DOCETAXEL**

In the TAX-327 trial, Tannock et al.\textsuperscript{15} randomized 1,006 men with mCRPC and good performance status to receive 5mg prednisone twice daily and either docetaxel 75mg/M\textsuperscript{2} every three weeks, docetaxel 30mg/M\textsuperscript{2} weekly, or mitoxantrone 12mg/M\textsuperscript{2} weekly. Patients who received docetaxel plus prednisone every three weeks in TAX-327 had significantly better survival than those receiving mitoxantrone (HR for death: 0.76; p=0.009). Median survival in the docetaxel plus prednisone every three weeks group was 18.9 months compared to 16.5 months in the mitoxantrone group. Analysis at longer follow-up demonstrated the median survival advantage improved slightly to 19.2 months compared to 16.3 months (P=.004).\textsuperscript{130} No significant survival differences were noted between the weekly docetaxel plus prednisone group and the mitoxantrone group. In a second study, SWOG 9916 tested docetaxel and estramustine versus mitoxantrone and prednisone for 12 cycles in 674 men with mCRPC.\textsuperscript{16} Patients in the docetaxel plus prednisone arm had improvements in median survival (17.5 versus 15.6 months, P=0.02) and time to progression (6.3 versus 3.2 months, p<0.001), and a 20% reduction in risk of death. The choice of initial treatment in this disease state should be driven by side effect profile and prior treatment. In TAX-327,\textsuperscript{15} 26% of patients in the docetaxel plus prednisone every three-weeks arm had one or more serious adverse events, and roughly 11% of patients in this group discontinued treatment due to adverse events. In contrast in COU-AA-302,\textsuperscript{127} although grades 3 to 4 mineralocorticoid-related adverse events and liver function abnormalities were more common in the abiraterone acetate group, the agent was generally well-tolerated. In PREVAIL, the most common adverse events associated with enzalutamide treatment included fatigue and hypertension.

A second issue is prior treatment. All of the trials above were performed prior to studies demonstrating the efficacy of apalutamide, darolutamide, enzalutamide, abiraterone acetate, and docetaxel in mHSPC and nmCRPC disease states. As such, the choice of subsequent therapy should be influenced by prior therapy, and clinicians should favor treatments that have a different mechanism of action than what was used previously.

**30. In mCRPC patients who are asymptomatic or minimally symptomatic, clinicians may offer sipuleucel-T. (Conditional Recommendation; Evidence Level: Grade B)**

Sipuleucel-T is an immunotherapy for the management of mCRPC. Sipuleucel-T immunotherapy is an FDA-approved agent in this setting based upon the results of the IMPACT trial,\textsuperscript{19} published in 2010. In this randomized double-blind placebo controlled clinical trial, 512 men with asymptomatic or minimally-symptomatic mCRPC and good functional status were randomized to receive either sipuleucel-T or placebo on a 2:1 basis. Compared to placebo, sipuleucel-T was associated with a relative reduction of 22% in the risk of death (HR=0.78; 95% CI: 0.61 to 0.98 P=0.03). Median survival in the sipuleucel-T arm was 25.8 months compared to 21.7 months in the placebo arm. It is worth noting that patients receiving sipuleucel-T therapy rarely (<10%) exhibit a clinical, serologic or radiographic response, and, as such, should be counseled appropriately not to expect to see a decline in PSA or reduction in radiologic volume of disease when undergoing this treatment. Enrollment was restricted to patients with ECOG performance status scores of 0 or 1 who were asymptomatic or minimally symptomatic; patients with visceral metastases were excluded. As such, sipuleucel-T should only be considered for patients with asymptomatic or minimally symptomatic mCRPC. Sipuleucel-T is not associated with objective anti-tumor response.
activity; its use is not appropriate for patients with large tumor burdens, those with visceral disease or with rapidly progressive disease. The use of sipuleucel-T immunotherapy is not recommended in symptomatic disease that necessitates opioid use, consistent with the FDA indication for this approach.

31. **Clinicians should offer radium-223 to patients with symptoms from bony metastases from mCRPC and without known visceral disease or lymphadenopathy >3cm.** (Strong Recommendation; Evidence Level: Grade B)

Radium-223 is an α-emitting radiopharmaceutical capable of inducing double strand DNA breaks in cancer cells while minimizing exposure to surrounding marrow. The use of radium-223 for the treatment of bone metastases relies on the chemical similarity to calcium and the ability of the α-radiation and the short-lived decay products of radium-223 to kill cancer cells. The short range of α-radiation reduces the damage to surrounding healthy tissue creating a more localized effect compared to other radionuclide therapies, such as strontium-89. This is an appropriate treatment for patients with symptomatic bone pain and non-visceral metastases.

A phase III trial with radium-223 in symptomatic men with progressive mCRPC with or without prior docetaxel exposure and no evidence of visceral metastasis reported improvement in median survival; 14.9 months versus 11.3 months (HR=0.70; 95% CI: 0.58 to 0.83; P<0.001) in favor of radium-223 over placebo. Time to first skeletal-related event (SRE) improved from 9.8 month with placebo to 15.6 months with radium-223 (HR=0.66; 95% CI: 0.52 to 0.83; P<0.001). Significant improvements in QOL measurements were reported in the patients treated with radium-223. Of the 921 patients of this trial, those receiving treatment were given 6 intravenous injections with a dose of 50 kBq per kilogram of body weight every 4 weeks. Rates of grade 3 or 4 neutropenia and thrombocytopenia were low at 2.2% and 6.3%, respectively.

As radium-223 targets bone only and is not associated with a PSA decline in a majority of patients, it is imperative for the clinician to carefully assess the patient on a monthly basis. Progression in non-bone sites is not infrequent during this six-month period of treatment. Given the lack of utility of PSA measurement in this space, the Panel recommends obtaining abdomen/pelvis CT imaging and chest x-ray even in the absence of symptoms prior to cycle four (of planned six monthly cycles) to assess for occult disease progression.

Clinicians should also be advised against concurrent use of abiraterone acetate plus prednisone in combination with radium-223 given the association with a higher risk of skeletal related events.

32. **Clinicians should offer 177Lu-PSMA-617 to patients with progressive mCRPC having previously received docetaxel and androgen pathway inhibitor with a positive PSMA PET imaging study.** (Strong Recommendation; Evidence Level Grade: B)

As previously discussed in statement 27, patients receiving 177Lu-PSMA-617 plus SOC in the phase III VISION study showed improved PFS and OS compared to patients receiving SOC alone at a median follow-up of approximately 21 months.

33. **In mCRPC patients who received prior docetaxel chemotherapy with or without prior abiraterone acetate plus prednisone or enzalutamide for the treatment of CRPC, clinicians may offer cabazitaxel.** (Conditional Recommendation; Evidence Level: Grade B)

Three cytotoxic chemotherapy regimens have been approved by the FDA for treatment of mCRPC: mitoxantrone, docetaxel, and cabazitaxel. Mitoxantrone was not associated with a survival benefit and is generally not recommended for most patients with mCRPC. Docetaxel is an effective option in both mCRPC and mHSPC and should be considered as standard first-line chemotherapy in the setting of mCRPC. Cabazitaxel was approved as second line chemotherapy in 2010 based on the results of the TROPIC trial. TROPIC randomized 755 men with mCRPC who had previously received docetaxel chemotherapy and demonstrated median survival of 15.1 months (95% CI: 14.1 to 16.3) in the cabazitaxel group and 12.7 months (11.6 to 13.7) in the mitoxantrone group. The HR for death of men treated with cabazitaxel compared with those taking mitoxantrone was 0.70 (95% CI: 0.59 to 0.83, p<0.0001). There was a clear OS benefit to cabazitaxel chemotherapy after docetaxel.
Abiraterone acetate and enzalutamide were not available at the time of the TROPIC trial, so it is unknown if this would have influenced the positive outcomes seen in TROPIC. It is also not clear if cabazitaxel given directly after docetaxel would be preferred over using ART therapy next, especially if the patient has never received next generation ART therapies such as abiraterone acetate or enzalutamide.

34. In mCRPC patients who received prior docetaxel chemotherapy and abiraterone acetate plus prednisone or enzalutamide, clinicians should recommend cabazitaxel rather than an alternative androgen pathway directed therapy. (Strong Recommendation; Evidence Level: Grade B)

Optimal third line therapy for mCRPC is unknown. The majority of patients will receive one ART targeted therapy with abiraterone acetate plus prednisone or enzalutamide and docetaxel chemotherapy. The CARD trial tested the efficacy and safety of cabazitaxel versus the alternative ART therapy in patients with mCRPC who progressed after two prior therapies. The primary end point was imaging-based PFS. Secondary end points included survival, response, and safety. A total of 255 patients were randomized, and progression or death was reported in 73.6% in the cabazitaxel group compared with 80.2% in the group that received a second ART (HR=0.54; 95% CI: 0.40 to 0.73; P<0.001). The median OS was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (HR for death=0.64; 95% CI: 0.46 to 0.89; P=0.008). The median PFS was 4.4 months with cabazitaxel and 2.7 months with an androgen-signaling-targeted inhibitor (HR for progression or death=0.52; 95% CI: 0.40 to 0.68; P<0.001). A PSA response occurred in 35.7% and 11.5% of the patients, respectively (P<0.001), and tumor response was noted in 36.5% and 11.5% (P=0.004). Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor.

It is important to note that the CARD study enrolled an enriched group of patients with advanced mCRPC, with more than two thirds having disease-related pain. There may be clinical settings as in long-term response to the initial agent (abiraterone acetate/enzalutamide) or asymptomatic patients with disease progression in whom a therapeutic trial of the alternative agent is reasonable.

Cabazitaxel significantly improved a number of clinical outcomes, as compared with an additional ART (abiraterone acetate or enzalutamide), in patients with mCRPC who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone acetate or enzalutamide). The magnitude of this benefit, improvement in multiple secondary endpoints, and other evidence demonstrating that sequencing serial ART therapies has limited efficacy suggests that cabazitaxel chemotherapy remains an important option for mCRPC patients in the third line.

35. Clinicians should offer a PARP inhibitor to patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated mCRPC following prior treatment with enzalutamide or abiraterone acetate, and/or a taxane-based chemotherapy. Platinum-based chemotherapy may be offered as an alternative for patients who cannot use or obtain a PARP inhibitor. (Moderate Recommendation; Evidence Level: Grade C)

PARP inhibitors leverage defects in DNA repair to provide a survival advantage in men with mCRPC who have mutations in DNA repair enzymes central to homologous recombination DNA repair. Defects in DNA repair occur in up to 30% of men with mCRPC, and such cancer cells depend instead on PARP-regulated DNA repair. Therefore, inhibition of PARP in these tumors results in cell death.

In the randomized, open-label, phase III PROfound trial, de Bono et al. randomly assigned 387 patients with progression on enzalutamide or abiraterone acetate in a 2:1 ratio to receive olaparib (300mg twice daily) or the physician’s choice of enzalutamide or abiraterone acetate (control). Nineteen percent of patients randomized to antiandrogen therapy had previously received both enzalutamide and abiraterone acetate; the trial did not report the proportion of patients among the remaining 81% who received the alternative antiandrogen or report results in this subgroup. All patients had a qualifying alteration in pre-specified genes with a direct or indirect role in homologous recombination repair. Cohort A had at least 1 alteration in BRCA1, BRCA2, or ATM; and cohort B had alterations in any of the 12 other pre-specified genes (BRIp1, BARD1, CDK12, CHEK1, CHEK2, FANCl, PALB2, PPP2R2A, RAD51B, RAD51C, RAD52, RAD53, TP53, MRE11A, and BLM).
RAD51D, or RAD54L). The primary endpoint was imaging-based PFS in cohort A. Median PFS was 7.4 months in the olaparib group versus 3.6 months in the control group (HR for progression or death=0.34; 95% CI: 0.25 to 0.47; P<0.001). Median overall survival in cohort A was 18.5 months with olaparib compared to 15.1 months in the control group. Investigators noted that anemia and nausea were the main toxic effects seen in patients on olaparib.

In addition to olaparib, rucaparib is also FDA approved for patients with deleterious BRCA mutation (germline and/or somatic)-associated mCRPC who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. This approval is based on results from the TRITON2 study, which as of the publication of this guideline, are currently only available in abstract form. Other PARP inhibitors (e.g., niraparib, veliparib, talozaparib) are currently under investigation.

Platinum-based chemotherapy also has a mechanism of action that correlates with defects in homologous recombination DNA repair. Preliminary data have demonstrated that, similar to PARP inhibition, carboplatin may improve outcomes in men with similar DNA defects. However, to date there are no randomized data supporting its use. In a retrospective analysis of a single-institution cohort of men with mCRPC, pathogenic germline BRCA2 variants were noted in 8 of 141 participants. Six of eight (75%) of those men experience PSA decline >50% within 12 weeks compared to 23 of 133 (17%) of non-carriers (absolute difference=58%; 95% CI: 27% to 88%; P<0.001).

36. In patients with mismatch repair deficient or MSI-H mCRPC, clinicians should offer pembrolizumab. (Moderate Recommendation; Evidence Level: Grade C)

Unlike the other major urologic neoplasms such as renal cell and urothelial cancers where next generation immunotherapy agents (check point inhibitors and anti-CTLA-4 agents) have demonstrated meaningful activity, there has been limited evidence of the utility of these therapies in mCRPC.

The MMR system is a post-replicative, single-strand repair mechanism that recognizes and reverses DNA base mismatches and insertions/deletions. Compromised MMR results in MSI and a hypermutator phenotype that has been associated with chemotherapy resistance but immunotherapy sensitivity.

In a case series of 1,033 patients with advanced prostate cancer 3.1% had an MSI-H/mismatch repair deficient (dMMR) prostate cancer, with more than half of those treated with anti PD-1 therapy responding to treatment having a >50% decline in PSA.

Until recently assessment of MSI status was a tissue-based assay and is still optimally done with archival or fresh tissue. Recent evidence suggests that cell-free DNA sequencing methods may allow MSI status to be determined with liquid biopsies.

In May 2017, the FDA approved pembrolizumab for patients with any metastatic MSI-H or dMMR histology that have progressed following prior treatment, and who have no satisfactory alternative treatment options.

**BONE HEALTH**

Several factors conspire to place the average patient with metastatic prostate cancer at a higher risk of bone complications. First, the median age of onset of the disease is in the late 60s, meaning that the average patient with metastatic disease may be in his 70s (or beyond), clearly a population at risk of physiologic, age-related decreases in bone mineral density. Secondly, a primary therapeutic intervention in patients with recurrent disease (e.g., ADT) is associated with progressive loss of bone mineral density, not infrequently to the point of measurable osteopenia or frank osteoporosis, increasing the patient’s fracture risk, even in patients with non-metastatic disease. Finally, in patients with advanced disease, bones are the most common site of metastatic disease, with many patients at some point in their course demonstrating evidence of disease in this site.

37. Clinicians should discuss the risk of osteoporosis associated with ADT and should assess the risk of fragility fracture in patients with advanced prostate cancer. (Clinical Principle)

Individuals with metastatic prostate cancer are at a high risk of bone complications due to age-related and treatment related loss in bone mineral density.

The Fracture Risk Assessment Tool (https://www.sheffield.ac.uk/FRAX/) is a validated tool.
resource to help predict a patient’s ten-year probability of hip fracture and the ten-year probability of a major osteoporotic-related fracture (e.g., spine, forearm, hip or shoulder fracture). This tool can be used with or without measurement of bone mineral density.

Baseline bone mineral density measurement with dual x-ray absorptiometry (DXA) may be considered in men receiving androgen deprivation and other systemic treatments for prostate cancer. Several observational studies have assessed changes in bone mineral density. Many of these studies reveal that the largest decrease in bone mineral density occurs within the first year of therapy, although bone loss has been observed beyond one year of therapy. Based on these observational studies, it would be reasonable to re-assess osteoporotic-related risk (FRAX® and DXA) one-year after initiating systemic treatment, and at longer intervals thereafter.

38. Clinicians should recommend preventative treatment for fractures and skeletal-related events, including supplemental calcium, vitamin D, smoking cessation, and weight-bearing exercise, to advanced prostate cancer patients on ADT. (Clinical Principle)

For patients with advanced prostate cancer, there is insufficient evidence to inform the optimal strategies for the prevention of bone loss and frailty fractures. However, for most patients, it is reasonable to inform patients about the tenets of bone health based on bone physiology, expert opinion, and syntheses of available clinical evidence.

The U.S. National Osteoporosis Foundation provides easy to use recommendations for bone health maintenance (https://www.nof.org/preventing-fractures/prevention/). Recommendations include weight bearing exercises, muscle building exercises, balance exercises, smoking cessation, reduction of alcohol intake, and adequate intake of calcium and vitamin D. The estimated daily calcium requirement is 1,000 to 1,200mg from food and supplements. The estimated daily vitamin D requirement is 1,000 IU from food, supplements, and sunlight.

39. In advanced prostate cancer patients at high fracture risk due to bone loss, clinicians should recommend preventative treatments with bisphosphonates or denosumab and referral to physicians who have familiarity with the management of osteoporosis when appropriate. (Clinical Principle)

Pharmacologic strategies for osteoporosis prevention and treatment include oral bisphosphonates (e.g., alendronate, pamidronate), intravenous bisphosphonates (e.g., zoledronic acid), and subcutaneous RANK ligand inhibitors (e.g., denosumab). It is important to note that the recommended dose and treatment schedules for zoledronic acid and denosumab are different for the indications of osteoporotic fracture prevention and SRE prevention. For example, zoledronic acid is usually administered yearly for osteoporosis-related fracture prevention compared to monthly or every three months for metastatic cancer SRE prevention. Similarly, denosumab has been administered as 60mg every 6 months for osteoporosis compared to 120mg monthly for SRE prevention.

A meta-analysis included 15 trials of 2,634 men with prostate cancer receiving ADT (with or without bone metastases) randomized to receive a bisphosphate versus placebo. Men receiving bisphosphonates had significantly reduced risk of osteoporosis (RR=0.39; 95% CI: 0.28 to 0.55; number needed to treat [NNT] to prevent one additional patient with osteoporosis: 2.82). Osteoporosis-related fractures were also reduced among patients treated with bisphosphonates (RR=0.80; 95% CI: 0.69 to 0.94; NNT to prevent one additional fracture: 167). Amongst bisphosphonates, the greatest reduction in fractures was observed for zoledronic acid (NNT: 14.9).

Denosumab increases bone mineral density in prostate cancer patients and reduces fracture risk as well. In a trial of 1,468 men receiving ADT for prostate cancer, patients were randomly assigned to denosumab (60mg every 6 months) versus placebo. After 36 months, men receiving denosumab significantly increased bone mineral density at all measured sites and decreased risk of vertebral fractures at 36 months following randomization (1.5% versus 3.9%; RR=0.38; 95% CI: 0.19 to 0.78; P=0.006).

Given the uncertainties of management of osteopenia and osteoporosis in prostate cancer patients at risk for bone
fractures, referral to physicians who have familiarity with management of osteoporosis should be considered for selected patients. These may include endocrinologists, orthopedic surgeons, primary care physicians, or other specialists who focus on bone health. Additionally, an uncommon but serious toxicity of bisphosphonates or denosumab is osteonecrosis of the jaw (ONJ). Because men who need dental extractions while on these agents are at higher risk for ONJ, clinicians should consider evaluation by a dentist prior to initiation.

40. Clinicians should prescribe a bone-protective agent (denosumab or zoledronic acid) for mCRPC patients with bony metastases to prevent skeletal-related events. (Moderate Recommendation; Evidence Level: Grade B)

Osteoclast-targeted agents were studied in men with mCRPC and bone metastases. In a phase III, double-blind, placebo-controlled trial, Saad et al.\textsuperscript{153} randomized patients with mCRPC to receive zoledronic acid at 4mg or placebo every 3 weeks for 15 months; the primary endpoint was the proportion of men experiencing at least 1 SRE. Men receiving zoledronic acid had significantly lower rates of SREs (33% with zoledronic acid versus 44% with placebo; \(P=0.021\)) and longer time to first SRE (>410 days with zoledronic acid and 321 days with placebo; \(P=0.011\)). The rate of pathologic fractures was also lower compared to placebo (13.1% with zoledronic acid versus 22.1% for placebo). Fizazi et al.\textsuperscript{154} performed a non-inferiority trial of 1,904 men with mCRPC with bone metastases randomized to receive denosumab or zoledronic acid with the primary endpoint of outcome of time to SRE. In addition to demonstrating that denosumab was non-inferior to zoledronic acid (20.7 versus 17.1 months; \(p=0.0002\)), this trial also showed that denosumab was superior to zoledronic acid in improving time to first SRE in a secondary analysis (\(p=0.008\)). Rates of hypocalcemia were higher with denosumab than zoledronic acid; as such, clinicians should monitor calcium levels prior to infusions, and repletion of vitamin D prior to starting these agents, along with SOC calcium and vitamin D maintenance.

In terms of schedule, CALGB 70604\textsuperscript{155} was a phase III, open-label trial that randomized 1,822 patients with metastatic breast or prostate cancer (\(n=686\)) or multiple myeloma to receive zoledronic acid every 4 weeks or every 12 weeks for 2 years. The trial demonstrated non-inferiority of 12-week dosing intervals for prevention of SREs. No differences were shown for secondary endpoints such as pain scores or performance status or toxicity including ONJ or renal dysfunction.

In the randomized, double-blinded, placebo-controlled phase III CALGB 90202 trial,\textsuperscript{156} 645 mHSPC patients were assigned 1:1 to receive either zoledronic acid (4mg intravenously every 4 weeks) or placebo. After progression to CRPC, all patients crossed over to open-label zoledronic acid. Median time to first SRE was 32.5 months in the zoledronic acid group and 29.8 months in the placebo group (HR=0.96; 95% CI: 0.76 to 1.22; \(P=0.74\)). OS was similar between groups (HR=0.89; 95% CI: 0.70 to 1.14; \(P=0.34\)). The study concluded that early treatment with zoledronic acid in men with HSPC and bone metastases was not associated with lower risk for SREs or death.

Future Directions

Several key areas of future research need emphasis to improve clinical care and provide a path to better patient outcomes with advanced prostate cancer.

Integration of Care

It is now clearer than ever that multimodality approaches and integration of care are critical to improving the outcomes for men with prostate cancer. Multidisciplinary clinics and the resulting multimodality treatment approaches can optimize treatment selection, maximize results, and reduce overtreatment and better manage side-effects.\textsuperscript{157} Many clinical trials are evaluating the concepts of integrating systemic therapy with radiation and/or surgery, such as optimizing treatment of men with locally advanced primary tumors, assessing the benefit of local therapy in men with metastatic disease, or determine the impact of metastasis-directed therapy in the oligometastatic setting. The results of these studies are likely to substantially impact the standard approaches to newly diagnosed patients with advanced disease.

Currently, surgical resection of the primary tumor in the setting of metastatic prostate cancer is considered experimental. There are several retrospective single-arm studies demonstrating safety and feasibility, and many studies from large population-based registries show that improved survival is associated with local control in metastatic prostate cancer patients.\textsuperscript{158-160} However, not all
studies have found a survival benefit, and all of these reports should be considered hypothesis-generating as they have unknown biases that make it difficult to apply the data into clinical practice. Several single-arm phase I/II trials and four randomized phase II clinical trials have been completed but are yet to be published. While the data mature, there is a phase III RCT—SWOG 1802—evaluating standard systemic therapy with or without local control of the primary in men with hormone-sensitive ‘de novo’ metastatic prostate cancer. There are also plans for a surgical treatment arm in the STAMPEDE study (NCT03678025). Local control in the SWOG 1802 study may consist of surgery, radiation, or both, based on physician discretion and patient choice. This study aims to address whether local treatment of the primary in the setting of metastatic prostate cancer provides a benefit, with OS as the primary endpoint. In the absence of prospective data demonstrating that surgery leads to an oncologic benefit in men with metastatic prostate cancer, its use should be restricted to clinical trials.

**Advanced PET Imaging and Theranostics**

PSMA PET imaging can identify sites of prostate cancer with superior specificity and sensitivity compared to conventional imaging. These findings are already impacting treatment planning by altering physician decision-making, but they have yet to demonstrate a clear benefit specific to patient outcomes. With recent expanded indications for PSMA PET imaging in newly diagnosed high-risk individuals, the impact and implications of additional findings remains to be determined. Use of these imaging agents will allow for identification of metastatic sites not otherwise seen with conventional imaging. As a result, it will be important to be cognizant of the stage migration that will occur with advanced PET imaging.

To date, there is a lack of prospective randomized data evaluating PET as a staging study for untreated prostate cancer, mHSPC or CRPC. What will ultimately determine the role of these PET agents will be trials demonstrating imaging improved patient outcomes as a direct result of earlier intensification of systemic therapies, MDT, and/or prediction of responses to specific therapies.

PSMA-based therapeutics, or theranostics, are a new treatment emerging from the ability to target PSMA expressed on the surface of cancer cells. These use the homing ability of PSMA-targeted antibodies or small molecules coupled to radioligands, such as Lutetium, to target prostate cancer cells systemically. Given the positive results of the VISION trial in advanced CRPC, research is now turning to its earlier use within the CRPC disease state as well as investigation into mHSPC, biochemical recurrence, and possibly even neoadjuvant therapy for high-risk localized disease. The durability of these treatments is being evaluated in multiple prospective clinical studies. This is another area in which integrated multidisciplinary care will be important and will require the expertise of multiple specialties (e.g., medical oncology, nuclear medicine, radiation oncology).

**Metastasis-directed Therapy**

Given the ability to identify metastatic sites earlier than was previously possible using newer PET imaging modalities, there has been renewed interest in the concept of MDT with radiation, surgery, or ablative technologies. The majority of data consists of retrospective studies to date. However, in M1 patients with hormone-sensitive oligometastatic disease (defined as <3 sites) after local treatment, two small randomized phase II trials tested whether MDT delays systemic treatment. Utilizing PET choline imaging in 62 patients, the STOMP trial found that median ADT-free survival was 13 months for the surveillance group and 21 months for the MDT group (HR=0.6; 80% CI: 0.40 to 0.90; P=0.11). OOL was comparable at baseline, 3 months and 1 year of follow-up. In the phase II ORIOLE trial 54 patients were randomized to receive stereotactic ablative radiotherapy (SABR) or observation alone using PSMA PET imaging. The primary endpoint was progression after 6 months, which was significantly lower with SBRT than with surveillance (19% versus 61%, P=0.005). It was also found that consolidation of all PSMA-positive disease decreased the risk of new lesions at 6 months (16% versus 63%; P=0.006).

PSMA and choline PET contribute to directing MDT. However, there is a lack of data regarding OS as well as selection criteria to identify those patients who will benefit. Therefore, MDT is not recommended outside of clinical trials until the results of several ongoing randomized trials become available. SOC (systemic therapy and prostate RT if low volume) ± SBRT to metastatic sites is being prospectively analyzed in phase III trials, including START MET (NCT05209243) and PRESTO (NCT04115007).
**Biomarkers and Other Systemic Therapies**

Given the dramatic increase in available therapies for advanced prostate cancer over the past ten years, there is a renewed urgency to identify predictive biomarkers that can guide treatment selection.

Currently, the most promising markers are those associated with clinical interventions such as identification of germline or somatic alterations within DDR genes (e.g., *BRCA1*, *BRCA2*, and *ATM*) providing evidence for PARP inhibitor use and MSI-H status providing evidence of immune checkpoint inhibitor use.

The potential importance of germline and somatic tumor testing, covered in guideline statements 13 and 28, largely surrounds their promise for predicting responses to PARP inhibitors such as olaparib, rucaparib, niraparib, veliparib, and talazoparib. Because PARP inhibitors, such as FDA approved agents olaparib and rucaparib, target the DNA replication machinery, tumors with deficiencies in homologous recombination repair (e.g., *BRCA1* or *BRCA2* mutations) are uniquely sensitive to PARP inhibition, a phenomenon termed synthetic lethality. In the TOPARP-A trial, heavily-treated mCRPC patients treated with olaparib were much more likely to respond in the setting of a DDR alteration. The response rate was 88% in biomarker positive patients and 6% in biomarker negative patients. Circulating cell-free DNA may be a future alternative approach for identifying these DDR alterations, and subsequent reversion mutations could be identified after disease progression. In the TOPARP-B study, which assessed 92 patients with DDR aberrations treated with olaparib, 44 patients (48%) demonstrated a confirmed response by imaging, PSA, or CTC criteria. Results of multiple prospective RCTs assessing PARP inhibitors in mCRPC patients with DDR alterations are pending.

In addition to PARP inhibitors, immunotherapies have also emerged as a key therapeutic modality in a large number of solid tumors. Aside from sipuleucel-T, these treatments have generally shown less efficacy in advanced prostate cancer compared to other malignancies, in part related to the relatively low tumor mutational burden of most prostate cancers. However, as described in guideline statement 36, there is likely to be a subset of prostate cancer patients who are uniquely sensitive to immunotherapy— particularly those patients who have tumors that have a high mutational burden.

(Insert Table 38)

**Unmet Needs**

While dramatic recent advances have been made, there are many unmet needs in prostate cancer management. Black patients with advanced prostate cancer demonstrate worse outcomes, and understanding the societal and biological underpinnings of these disparities is a critical area of need. Personalized care with predictive markers for treatment selection based on tumor and host biology have not yet been achieved. There has been movement toward identification of prognostic markers and identification of molecular markers based on immunohistochemistry and use of genomic signatures, but these have yet to yield predictive results. PSMA imaging is changing the landscape of advanced prostate cancer. As we learn more about its utility in the management of these patients, we will soon also be able to treat these patients with precision-guided therapy. The emerging field of theranostics will add further benefit and complexity to the sequencing dilemmas. Emerging evidence supports the use of SBRT as MDT for oligometastatic genitourinary cancers in a phase II trial. With the widening use of next-generation imaging, application of MDT as SOC requires definitive trials. Improving responses by treating high-risk patients in a neoadjuvant approach prior to surgery based on tumor susceptibilities is another area of developing interest.

There are many additional unmet needs. These include high-level evidence directed at understanding the optimal sequencing of advanced prostate cancer therapies. Further, we need additional studies and data to guide clinicians and patients in terms of treatment intensification and combinations of therapy. Improving access to care for those who are socioeconomically disadvantaged is also a future goal.
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>95% CI</td>
<td>95% confidence interval</td>
</tr>
<tr>
<td>ADT</td>
<td>Androgen deprivation therapy</td>
</tr>
<tr>
<td>AR</td>
<td>Androgen receptor</td>
</tr>
<tr>
<td>ART</td>
<td>Androgen receptor-targeted therapy</td>
</tr>
<tr>
<td>ASCO</td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td>ASTRO</td>
<td>American Society for Radiation Oncology</td>
</tr>
<tr>
<td>AUA</td>
<td>American Urological Association</td>
</tr>
<tr>
<td>AUER</td>
<td>American Urological Association Education and Research, Inc.</td>
</tr>
<tr>
<td>AUROC</td>
<td>Area under the receiver operating characteristic curve</td>
</tr>
<tr>
<td>BOD</td>
<td>Board of Directors</td>
</tr>
<tr>
<td>CaPSURE</td>
<td>Cancer of the Prostate Strategic Urologic Research Endeavor</td>
</tr>
<tr>
<td>CRPC</td>
<td>Castration-resistant prostate cancer</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>CTC</td>
<td>Circulating tumor cells</td>
</tr>
<tr>
<td>DDR</td>
<td>DNA damage repair</td>
</tr>
<tr>
<td>dMMR</td>
<td>Mismatch repair deficient</td>
</tr>
<tr>
<td>DXA</td>
<td>Dual x-ray absorptiometry</td>
</tr>
<tr>
<td>EBRT</td>
<td>External beam radiotherapy</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>GnRH</td>
<td>Gonadotropin-releasing hormone</td>
</tr>
<tr>
<td>HR</td>
<td>Hazard ratio</td>
</tr>
<tr>
<td>HSPC</td>
<td>Hormone-sensitive prostate cancer</td>
</tr>
<tr>
<td>ICECaP</td>
<td>Intermediate clinical endpoints in cancer of the prostate</td>
</tr>
<tr>
<td>ISUP</td>
<td>International Society of Urologic Pathologists</td>
</tr>
<tr>
<td>LHRH</td>
<td>Luteinizing hormone-releasing hormone</td>
</tr>
<tr>
<td>mCRPC</td>
<td>Metastatic castration-resistant prostate cancer</td>
</tr>
<tr>
<td>MDT</td>
<td>Metastasis-directed therapy</td>
</tr>
<tr>
<td>MFS</td>
<td>Metastasis-free survival</td>
</tr>
<tr>
<td>mHSPC</td>
<td>Metastatic hormone-sensitive prostate cancer</td>
</tr>
<tr>
<td>MMR</td>
<td>Mismatch repair</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>MSI-H</td>
<td>Microsatellite instability-high</td>
</tr>
<tr>
<td>nmCRPC</td>
<td>Non-metastatic castration-resistant prostate cancer</td>
</tr>
<tr>
<td>NNT</td>
<td>Number needed to treat</td>
</tr>
<tr>
<td>OS</td>
<td>Overall survival</td>
</tr>
<tr>
<td>PARP</td>
<td>Poly (ADP-ribose) polymerase</td>
</tr>
<tr>
<td>PFS</td>
<td>Progression-free survival</td>
</tr>
<tr>
<td>PET</td>
<td>Positron emission tomography</td>
</tr>
<tr>
<td>PGC</td>
<td>Practice Guidelines Committee</td>
</tr>
<tr>
<td>PICOTS</td>
<td>populations, interventions, comparators, outcomes, timing, and settings</td>
</tr>
<tr>
<td>PSA</td>
<td>Prostate-specific antigen</td>
</tr>
<tr>
<td>PSADT</td>
<td>PSA doubling-time</td>
</tr>
<tr>
<td>PSMA</td>
<td>Prostate-specific membrane antigen</td>
</tr>
<tr>
<td>QOL</td>
<td>Quality of life</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized controlled trial</td>
</tr>
<tr>
<td>SOC</td>
<td>Standard of care</td>
</tr>
<tr>
<td>SQC</td>
<td>Science &amp; Quality Council</td>
</tr>
<tr>
<td>SRE</td>
<td>Skeletal-related event</td>
</tr>
<tr>
<td>SUO</td>
<td>Society of Urologic Oncology</td>
</tr>
</tbody>
</table>
Advanced Prostate Cancer

ADVANCED PROSTATE CANCER PANEL, CONSULTANTS, AND STAFF

Panel 2020
William Lowrance, MD, MPH, MBA (Chair)
University of Utah
Salt Lake City, UT

Michael S. Cookson, MD, MMHC (Vice Chair)
Oklahoma University
Oklahoma City, OK

Rodney H. Breau, MSc, MD (PGC Rep)
University of Ottawa
Ottawa, ON

Tony Crispino (Patient Advocate)
UsTOO Las Vegas
Las Vegas, NV

Brian F. Chapin, MD
University of Texas MD Anderson Cancer Center
Houston, TX

Robert Dreicer, MD, MS, MACP
University of Virginia Medical School
Charlottesville, VA

David F. Jarrard, MD
University of Wisconsin School of Medicine
Madison, WI

Adam S. Kibel, MD
Brigham and Women’s Hospital
Boston, MA

Todd M. Morgan, MD
University of Michigan Urology Cancer Center
Ann Arbor, MI

Alicia K. Morgans, MD, MPH
Northwestern University Feinberg School of Medicine
Chicago, IL

William K. Oh, MD
Icahn School of Medicine at Mount Sinai
New York, NY

Matthew Resnick, MD, MPH, MMHC
Vanderbilt University Medical Center
Nashville, TN

Anthony Zietman, MD
Massachusetts General Hospital
Boston, MA

Consultants 2020
Roger Chou, MD
Pacific Northwest Evidence-based Practice Center

Jessica C. Griffin, MS
Pacific Northwest Evidence-based Practice Center

Staff 2020
Abid Khan, MHS, MPP
Erin Kirkby, MS

Amendment Panel 2023
William Lowrance, MD, MPH, MBA (Chair)
Bon Secours Mercy Health
Greenville, SC

Michael S. Cookson, MD, MMHC (Vice Chair)
Oklahoma University
Oklahoma City, OK

Robert Dreicer, MD, MS, MACP
University of Virginia Medical School
Charlottesville, VA

David F. Jarrard, MD
University of Wisconsin School of Medicine
Madison, WI

Kristen R. Scarpato, MD, MPH
Vanderbilt University Medical Center
Nashville, TN

Consultants 2023
David I. Buckley, MD, MPH
Pacific Northwest Evidence-based Practice Center

Jessica C. Griffin, MS
Pacific Northwest Evidence-based Practice Center

Staff 2023
Erin Kirkby, MS
Sennett K. Kim
Brooke Bixler, MPH
Leila Rahimi, MHS
Chelsi Matthews
CONFLICT OF INTEREST DISCLOSURES

2020

All panel members completed COI disclosures. Disclosures listed include both topic– and non-topic-related relationships. Panel members not listed below have nothing to disclose.

Consultant/Advisor: Rodney Breau, Ferring; Brian Chapin, Blue Earth Diagnostic; Michael Cookson, TesoRx Pharma, Astellas, Merck, Bayer, Ferring, Myovant; Robert Dreicer, Astra Zeneca, Janssen, Eisai, Pfizer, Seattle Genetics; David Jarrard, Gregor Diagnostics; Adam Kibel, Projound, Janssen, ConfirmMDx, Insight Diagnostics, Merck; Alicia Morgans, Bayer, Astra Zeneca, Astellas, Sanofi, Genentech, Janssen, Clovis, Dendreon, Merck, BMS, Pfizer, Myovant, Advanced Accelerator Applications; William Oh, Sanofi-Aventis, Astellas, Bayer, Janssen, Astra Zeneca, Bellicum, CheckPoint Sciences, Sema4, TeneoBio, The Foundry; Matthew Resnick, MDx Health

Scientific Study or Trial: Brian Chapin, Janssen; William Lowrance, Myriad Genetics; Todd Morgan, GenomeDx; Matthew Resnick, Genomic Health

Investment Interest: William Lowrance, Stream Dx

Health Publishing: Rodney Breau, Journal of Urology

Leadership Position: Todd Morgan, Visible Health, Inc.; Matthew Resnick, Embold Health; Anthony Zietman, ASTRO

Other: Adam Kibel, Bristol-Myers Squibb, Advantagene

CONFLICT OF INTEREST DISCLOSURES

2023

Consultant/Advisor: Michael Cookson, Pfizer, Nonagen Bioscience Corp., Natera, Inc.; Robert Dreicer, Pfizer, Astellas, Aveo, Bayer, Exelixis, Janssen, Hinova, Merck, Propella, Tavanta; David Jarrard, Gregor Diagnostics; Kristen Scarpato, CxBladder

Scientific Study or Trial: Kristen Scarpato, CxBladder

Owner: William Lowrance, Stream Dx

Meeting Participant or Lecturer: Michael Cookson, Remedica Medical Education and Publishing Ltd.; Kristen Scarpato, Photocure

2020 PEER REVIEWERS

We are grateful to the persons listed below who contributed to the Guideline by providing comments during the peer review process. Their reviews do not necessarily imply endorsement of the Guideline.

AUA (Board of Directors, Science and Quality Council, Practice Guidelines Committee, Journal of Urology)

Peter E. Clark, MD
John Denstedt, MD
James Eastham, MD
Robert C. Flanigan, MD
David A. Ginsberg, MD
Melissa R. Kaufman, MD
Louis R. Kavoussi, MD
Badrinath Konety, MD
Roger E. Schultz, MD
Anthony Y. Smith, MD

External Reviewers (Non-AUA Affiliates)

Mitch Anscher, MD
Karen Autio, MD
Rick Bangs
Mark Buyyounouski, MD
Sam Chang, MD
Kim Chi, MD
Scott Delacroix, MD
Tanya Dorff, MD
Chris Evans, MD
John Flöberg, MD
Jeff Jones, MD
William Kelly, MD
Luke Lavallee, MD
Richard Lee, MD
Alejandro Sanchez, MD
Ted Schaeffer, MD
Mark Tyson, MD
Young Whang, MD
Michael Williams, MD
Evan Yu, MD

Public Commenters (Via public notice on AUA website)

Lisa Meadows Ambrose, PharmD-c
Andree Amelsberg, MD
Josefa Briceno, MD
Mildred Costello, PharmD
Lori Ellis, PhD
Denise D’Andrea, MD
DISCLAIMER

This document was written by the Advanced Prostate Cancer Panel of the American Urological Association Education and Research, Inc., which was created in 2020. The PGC of the AUA selected the Panel Chair. Panel members were selected by the Panel and PGC Chair.

Membership of the panel included specialists with specific expertise on this disorder. The mission of the panel was to develop recommendations that are analysis-based or consensus-based, depending on panel processes and available data, for optimal clinical practices in the diagnosis and treatment of advanced prostate cancer.

Funding of the panel was provided by the AUA. Panel members received no remuneration for their work. Each member of the panel provides an ongoing conflict of interest disclosure to the AUA.

While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated. As medical knowledge expands and technology advances, the guidelines will change. Today these evidence-based guideline statements represent not absolute mandates but provisional proposals for treatment under the specific conditions described in each document. For all these reasons, the guidelines do not pre-empt physician judgment in individual cases.

Treating physicians must take into account variations in resources, and patient tolerances, needs, and preferences. Conformance with any clinical guideline does not guarantee a successful outcome. The guideline text may include information or recommendations about certain drug uses (‘off label’) that are not approved by the Food and Drug Administration (FDA), or about medications or substances not subject to the FDA approval process. AUA urges strict compliance with all government regulations and protocols for prescription and use of these substances. The physician is encouraged to carefully follow all available prescribing information about indications, contraindications, precautions and warnings. These guidelines and best practice statements are not intended to provide legal advice about use and misuse of these substances.
Although guidelines are intended to encourage best practices and potentially encompass available technologies with sufficient data as of close of the literature review, they are necessarily time-limited. Guidelines cannot include evaluation of all data on emerging technologies or management, including those that are FDA-approved, which may immediately come to represent accepted clinical practices.

For this reason, the AUA does not regard technologies or management that are too new to be addressed by this guideline as necessarily experimental or investigational.
References


36 Shea BJ, Reeves BC, Wells G et al: AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017; 358.


66 Duchesne GM, Woo HH, King M et al: Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01–03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 2017; **18**:1192.


108 Tyrrell CJ, Iversen P, Tammela T et al: Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int 2006;98:563.


161 Yuh BE, Kwon YS, Shinder BM et al: Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate Int. 2019;7:102.


Hofman MS, Murphy DG, Williams SG et al: A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. 2018;122:783.


